# List of phenyltropanes

Phenyltropanes (PTs) are a family of chemical compounds originally derived from structural modification of cocaine. The main feature differentiating phenyltropanes from cocaine is that they lack the ester functionality at the 3-position terminating in the benzene; and thusly the phenyl is attached direct to the tropane skeleton with no further spacer (therefore the name "phenyl"-tropane) that the cocaine benzoyloxy provided. The original purpose of which was to extirpate the cardiotoxicity inherent in the local anesthetic "numbing" capability of cocaine (since the methylated benzoate ester is essential to cocaine's blockage of sodium channels which cause topical anesthesia) while retaining stimulant function. These compounds present many different avenues of research into therapeutic applications, particularly in addiction treatment. Uses vary depending on their construction and structure-activity relationship ranging from the treating of cocaine dependency to understanding the dopamine reward system in the human brain to treating Alzheimer's and Parkinson's diseases. (Since 2008 there have been continual additions to the list and enumerations of the plethora of types of chemicals that fall into the category of this substance profile.) Certain phenyltropanes can even be used as a smoking cessation aid (c.f. RTI-29). Many of the compounds were first elucidated in published material by the Research Triangle Institute and are thus named with "RTI" serial-numbers (in this case the long form is either RTI-COC-n, for 'cocaine' "analog", or specifically RTI-4229-n of the subsequent numbers given below in this article) Similarly, a number of others are named for Sterling-Winthrop pharmaceuticals ("WIN" serial-numbers) and Wake Forest University ("WF" serial-numbers). The following includes many of the phenyltropane class of drugs that have been made and studied.
* 3D rendering of troparil; which comprises a privileged scaffold of among the phenyltropane class of compounds.
* Troparil structure: c.f. U.S. patent 5,496,953

## 2-Carboxymethyl esters (phenyl-methylecgonines)

* Epibatropane containing a nitrogen heteroatom in the benzene ring formation.
* Tamagnan: SSRI, SERT = 17(pM) = 10 times the strength of paroxetine for 5HT.
* RTI-298
* (4′-)para-cis-propenyl-phenyl-methylecgonine. A rare SDRI compound with negligible NET affinity (>2,800.0nM displacement value for NET ligand) that retains significant DAT & SERT (15.0nM & 7.1nM) affinity.
* C2-C3 unsaturated (non-isomeric, neither α nor β orientated) 2-naphthyl-tropane
* 1-naphthyl-tropane in its usual (comparably non-standard) boat formation of its tropane ring.
Like cocaine, phenyltropanes are considered a 'typical' or 'classical' (i.e. "cocaine-like") DAT re-uptake pump ligands in that they stabilize an "open-to-out" conformation on the dopamine transporter; despite the extreme similarity to phenyltropanes, benztropine and others are in suchwise not considered "cocaine-like" and are instead considered atypical inhibitors insofar as they stabilize what is considered a more inward-facing (closed-to-out) conformational state.
Considering the differences between PTs and cocaine: the difference in the length of the benzoyloxy and the phenyl linkage contrasted between cocaine and phenyltropanes makes for a shorter distance between the centroid of the aromatic benzene and the bridge nitrogen of the tropane in the latter PTs. This distance being on a scale of 5.6 Å for phenyltropanes and 7.7 Å for cocaine or analogs with the benzoyloxy intact. The manner in which this sets phenyltropanes into the binding pocket at MAT is postulated as one possible explanation to account for PTs increased behavioral stimulation profile over cocaine.
Blank spacings within tables for omitted data use "no data", "?", "-" or "—" interchangeably.
2β-carbmethoxy-3β-(4′-substituted phenyl)tropanes (IC$_{50}$ values) monohalogen halide-phenyltropanes (11a—11e) alkyl-, & alkenyl-phenyltropanes (11r—11x) alkynyl-phenyltropanes (11y & 11z) :
| Short Name i.e. Trivial IUPAC (non-systematic) Name (Singh's #) | R (para-substitution) of benzene | DA [$^3$H]WIN 35428 IC$_{50}$ nM (K$_i$ nM) | 5HT [$^3$H]paroxetine IC$_{50}$ nM (K$_i$ nM) | NE [$^3$H]nisoxetine IC$_{50}$ nM (K$_i$ nM) | selectivity 5-HTT/DAT | selectivity NET/DAT |
| cocaine (benzoyloxytropane) | H | 102 ± 12 241 ± 18$^ɑ$ | 1045 ± 89 112 ± 2$^b$ | 3298 ± 293 160 ± 15$^c$ | 10.2 0.5$^d$ | 32.3 0.7$^e$ |
| (para-hydrogen)phenyltropane WIN 35,065-2 (β-CPT) Troparil 11a | H | 23 ± 5.0 49.8 ± 2.2$^ɑ$ | 1962 ± 61 173 ± 13$^b$ | 920 ± 73 37.2 ± 5.2$^c$ | 85.3 3.5$^d$ | 40.0 0.7$^e$ |
| para-fluorophenyltropane WIN 35,428 (β-CFT) 11b | F | 14 (15.7 ± 1.4) 22.9 ± 0.4$^ɑ$ | 156 (810 ± 59) 100 ± 13$^b$ | 85 (835 ± 45) 38.6 ± 9.9$^c$ | 51.6 4.4$^d$ | 53.2 1.7$^e$ |
| para-nitrophenyltropane 11k | NO$_2$ | 10.1 ± 0.10 | ? | ? | ? | ? |
| para-aminophenyltropane RTI-29 11j | NH$_2$ | 9.8 24.8 ± 1.3$^g$ | 5110 | 151 | 521.4 | 15.4 |
| para-chlorophenyltropane RTI-31 11c | Cl | 1.12 ± 0.06 3.68 ± 0.09$^ɑ$ | 44.5 ± 1.3 5.00 ± 0.05$^b$ | 37 ± 2.1 5.86 ± 0.67$^c$ | 39.7 1.3$^d$ | 33.0 1.7$^e$ |
| para-methylphenyltropane RTI-32 Tolpane 11f | Me | 1.71 ± 0.30 7.02 ± 0.30$^ɑ$ | 240 ± 27 19.38 ± 0.65$^b$ | 60 ± 0.53$^e$ 8.42 ± 1.53$^c$ | 140 2.8$^d$ | 35.1 1.2$^e$ |
| para-bromophenyltropane RTI-51 Bromopane 11d | Br | 1.81 (1.69) ± 0.30 | 10.6 ± 0.24 | 37.4 ± 5.2 | 5.8 | 20.7 |
| para-iodophenyltropane RTI-55 (β-CIT) Iometopane 11e | I | 1.26 ± 0.04 1.96 ± 0.09$^ɑ$ | 4.21 ± 0.3 1.74 ± 0.23$^b$ | 36 ± 2.7 7.51 ± 0.82$^c$ | 3.3 0.9$^d$ | 28.6 3.8$^e$ |
| para-hydroxyphenyltropane 11h | OH | 12.1 ± 0.86 | — | — | — | — |
| para-methoxyphenyltropane 11i | OCH$_3$ | 8.14 ± 1.3 | — | — | — | — |
| para-azidophenyltropane 11l | N$_3$ | 2.12 ± 0.13 | — | — | — | — |
| para-trifluoromethylphenyltropane 11m | CF$_3$ | 13.1 ± 2.2 | — | — | — | — |
| para-acetylaminophenyltropane 11n | NHCOCH$_3$ | 64.2 ± 2.6 | — | — | — | — |
| para-propionylaminophenyltropane 11o | NHCOC$_2$H$_5$ | 121 ± 2.7 | — | — | — | — |
| para-ethoxycarbonylaminophenyltropane 11p | NHCO$_2$C$_3$H$_5$ | 316 ± 48 | — | — | — | — |
| para-trimethylstannylphenyltropane 11q | Sn(CH$_3$)$_3$ | 144 ± 37 | — | — | — | — |
| para-ethylphenyltropane RTI-83 11g | Et | 55 ± 2.1 | 28.4 ± 3.8 (2.58 ± 3.5) | 4030 (3910) ± 381 (2360 ± 230) | 0.5 | 73.3 |
| para-n-propylphenyltropane RTI-282$^i$ 11r | n-C$_3$H$_7$ | 68.5 ± 7.1 | 70.4 ± 4.1 | 3920 ± 130 | 1.0 | 57.2 |
| para-isopropylphenyltropane 11s | CH(CH$_3$)$_2$ | 597 ± 52 | 191 ± 9.5 | 75000 ± 5820 | 0.3 | 126 |
| para-vinylphenyltropane RTI-359 11t | CH-CH$_2$ | 1.24 ± 0.2 | 9.5 ± 0.8 | 78 ± 4.1 | 7.7 | 62.9 |
| para-methylethenylphenyltropane RTI-283$^j$ 11u | C(=CH$_2$)CH$_3$ | 14.4 ± 0.3 | 3.13 ± 0.16 | 1330 ± 333 | 0.2 | 92.4 |
| para-trans-propenylphenyltropane RTI-296$^i$ 11v | trans-CH=CHCH$_3$ | 5.29 ± 0.53 | 11.4 ± 0.28 | 1590 ± 93 | 2.1 | 300 |
| para-allylphenyltropane 11x | CH$_2$CH=CH$_2$ | 32.8 ± 3.1 | 28.4 ± 2.4 | 2480 ± 229 | 0.9 | 75.6 |
| para-ethynylphenyltropane RTI-360 11y | C≡CH | 1.2 ± 0.1 | 4.4 ± 0.4 | 83.2 ± 2.8 | 3.7 | 69.3 |
| para-propynylphenyltropane RTI-281$^i$ 11z | C≡CCH$_3$ | 2.37 ± 0.2 | 15.7 ± 1.5 | 820 ± 46 | 6.6 | 346 |
| para-cis-propenylphenyltropane RTI-304 11w | cis-CH=CHCH$_3$ | 15 ± 1.2 | 7.1 ± 0.71 | 2,800$^k$ ± 300 | 0.5 | 186.6$^k$ |
| para-(Z)-phenylethenylphenyltropane | cis-CH=CHPh | 11.7 ± 1.12 | — | — | — | — |
| para-benzylphenyltropane | -CH$_2$-Ph | 526 ± 65 | 7,240 ± 390 (658 ± 35) | 6670 ± 377 (606 ± 277) | 13.7 | 12.6 |
| para-phenylethenylphenyltropane | CH$_2$ ║ -C-Ph | 474 ± 133 | 2,710 ± 800 (246 ± 73) | 7,060 ± 1,760 (4,260 ± 1,060) | 5.7 | 14.8 |
| para-phenylethylphenyltropane$^l$ | -(CH$_2$)$_2$-Ph | 5.14 ± 0.63 | 234 ± 26 (21.3 ± 2.4) | 10.8 ± 0.3 (6.50 ± 0.20) | 45.5 | 2.1 |
| para-(E)-phenylethenylphenyltropane$^l$ RTI-436 | trans–CH=CHPh | 3.09 ± 0.75 | 335 ± 150 (30.5 ± 13.6) | 1960 ± 383 (1180 ± 231) | 108.4 | 634.3 |
| para-phenylpropylphenyltropane$^l$ | -(CH$_2$)$_3$-Ph | 351 ± 52 | 1,243 ± 381 (113 ± 35) | 14,200 ± 1,800 (8,500 ± 1,100) | 3.5 | 40.4 |
| para-phenylpropenylphenyltropane$^l$ | -CH=CH-CH$_2$-Ph | 15.8 ± 1.31 | 781 ± 258 (71 ± 24) | 1,250 ± 100 (759 ± 60) | 49.4 | 79.1 |
| para-phenylbutylphenyltropane$^l$ | -(CH$_2$)$_4$-Ph | 228 ± 21 | 4,824 ± 170 (439 ± 16) | 2,310 ± 293 (1,390 ± 177) | 21.1 | 10.1 |
| para-phenylethynylphenyltropane$^l$ RTI-298 | –≡–Ph | 3.7 ± 0.16 | 46.8 ± 5.8 (4.3 ± 0.53) | 347 ± 25 (209 ± 15) | 12.6 | 93.7 |
| para-phenylpropynylphenyltropane$^l$ | –C≡C-CH$_2$Ph | 1.82 ± 0.42 | 13.1 ± 1.7 (1.19 ± 0.42) | 27.4 ± 2.6 (16.5 ± 1.6) | 7.1 | 15 |
| para-phenylbutynylphenyltropane$^l$ RTI-430 | –C≡C(CH$_2$)$_2$Ph | 6.28 ± 1.25 | 2180 ± 345 (198 ± 31) | 1470 ± 109 (885 ± 66) | 347.1 | 234 |
| para-phenylpentynylphenyltropane$^l$ | –C≡C-(CH$_2$)$_3$-Ph | 300 ± 37 | 1,340 ± 232 (122 ± 21) | 4,450 ± 637 (2,680 ± 384) | 4.46 | 14.8 |
| para-trimethylsilylethynylphenyltropane | — | — | — | — | — | — |
| para-hydroxypropynylphenyltropane | — | — | — | — | — | — |
| para-hydroxyhexynylphenyltropane$^l$ | –C≡C-(CH$_2$)$_4$OH | 57 ± 4 | 828 ± 29 (75 ± 2.6) | 9,500 ± 812 (5,720 ± 489) | 14.5 | 166.6 |
| para-(thiophen-3-yl)phenyltropane Tamagnan | p-thiophene | 12 | 0.017 | 189 | 0.001416 | 15.7 |
| para-biphenyltropane 11aa | Ph | 10.3 ± 2.6$^f$ 29.4 ± 3.8$^ɑ$ 15.6 ± 0.6 | 95.8 ± 36 (8.7 ± 3.3) | 1,480 ± 269 (892 ± 162) | 6.1 | 94.8 |
| 3β-2-naphthyltropane RTI-318 11bb | 3β-2-naphthyl | 0.51 ± 0.03 3.32 ± 0.08$^f$ 3.53 ± 0.09$^ɑ$ | 0.80 ± 0.06 (0.07 ± 0.1) | 21.1 ± 1.0 (12.7 ± 0.60) | 1.5 | 41.3 |
| para-bimethoxyphenyltropane 15 | OCH$_2$OCH$_3$$^h$ | — | — | — | — | — |
| $^ɑ$[$^3$H]DA uptake displacement K$_i$ value. $^b$[$^3$H]5-HT uptake displacement K$_i$ value. $^c$[$^3$H]NE uptake displacement K$_i$ value. | $^d$[$^3$H]5-HT uptake to [$^3$H]DA uptake ratio. $^e$[$^3$H]NE uptake to [$^3$H]DA uptake ratio. $^f$IC$_{50}$ for displacement of [$^3$H]cocaine. $^g$Values from alternate data-set differing from that used in rest of table. $^h$Original source (Scheme 4, page 931, 7th of article) name given for compound (bottom of first ¶) is at variance with formula in scheme on same page: i.e. "methoxymethyl" versus "methoxymethoxy" | $^i$Protonated as the (-)—tartrate salt (isomer) $^j$Protonated as the tartrate salt $^k$Was cited by S. Singh as 28,000nM for SERT or a DAT/SERT ratio of 1,867. However, in Singh's paper he cited J. Med. Chem. 1996, 39, 4030, Table 1 which shows a ten times lower value, which is consistent with numerous RTI patents published showing the ten-× lower value. $^l$Whereas many bulky additions to the arene unit of phenyltropanes hinder and impair affinity, it has been observed that the para-substituted rigid triple bond analogs terminating in a second phenyl (off of the initial C3 position phenyl) have a high-binding affinity, putatively attesting to the existence of another binding domain that extends beyond the usual ending point where the benzene accords to the acceptor somewhere along the length of range inhabited by the DAT, corresponding to a 180° extension outward from the para area of the aryl of these type of ligands. |

### (4′-Monosubstituted 2,3-Thiophene phenyl)-tropanes

Tamagnan (thiophene) analogues of para-phenyltropanes. :
| Alphanumeric code (name) | para-substitution | N8 | SERT | DAT | NET | Selectivity SERT versus DAT | Selectivity SERT versus NET |
| 1 (cocaine) | (—)-Cocaine | CH$_3$ | 1050 | 89 | 3320 | 0.08 | 3.2 |
| 2 (β-CIT), (Iometopane) | Iodo | CH$_3$ | 0.46 ± 0.06 | 0.96 ± 0.15 | 2.80 ± 0.40 | 2.1 | 6.1 |
| (R,S-Citalopram) | — | — | 1.60 | 16,540 | 6,190 | 10,338 | 3,869 |
| 4a | 2-Thiophene | CH$_3$ | 0.15 ± 0.015 | 52 ± 12.8 | 158 ± 12 | 346 | 1,053 |
| 4b (Tamagnan) | 3-Thiophene | CH$_3$ | 0.017 ± 0.004 | 12.1 ± 3 | 189 ± 82 | 710 | 11,118 |
| 4c | 2-(5-Br)-Thiophene | CH$_3$ | 0.38 ± 0.008 | 6.43 ± 0.9 | 324 ± 19 | 17 | 853 |
| 4d | 2-(5-Cl)-Thiophene | CH$_3$ | 0.64 ± 0.04 | 4.42 ± 1.64 | 311 ± 25 | 6.9 | 486 |
| 4e | 2-(5-I)-Thiophene | CH$_3$ | 4.56 ± 0.84 | 22.1 ± 3.2 | 1,137 ± 123 | 4.9 | 249 |
| 4f | 2-(5-NH$_2$)-Thiophene | CH$_3$ | 64.7 ± 3.7 | >10,000 | >30,000 | >155 | >464 |
| 4g | 2-(4,5-NO$_2$)-Thiophene | CH$_3$ | 5,000 | >30,000 | >10,000 | >6.0 | >2.0 |
| 4h | 3-(4-Br)-Thiophene | CH$_3$ | 4.02 ± 0.34 | 183 ± 69 | >10,000 | 46 | >2,488 |
| 5a | 2-Thiophene | H | 0.11 ± 0.006 | 12.2 ± 0.9 | 75.3 ± 9.6 | 111 | 685 |
| 5b | 3-Thiophene | H | 0.23 ± 0.02 | 6.4 ± 0.27 | 39 ± 0.8 | 28 | 170 |

### (3′,4′-Disubstituted phenyl)-tropanes

| Compound (+ S. Singh's name) | X (4′-para) | Y (3′-meta) | 2 Position | config | 8 | DA | 5-HT | NE |
| RTI-318 11bb | β-naphthyl | β-naphthyl | CO$_2$Me | β,β | NMe | 0.5 | 0.81 | 20 |
| Dichloropane (RTI-111$^ɑ$) 17c | Cl | Cl | CO$_2$Me | β,β | NMe | 0.79 | 3.13 | 18.0 |
| RTI-88 [recheck] 17e | NH$_2$ | I | CO$_2$Me | β,β | NMe | 1.35 | 1329$^c$ | 320$^c$ |
| RTI-97 17d | NH$_2$ | Br | CO$_2$Me | β,β | NMe | 3.91 | 181 | 282 |
| RTI-112$^b$ 17b | Cl | Me | CO$_2$Me | β,β | NMe | 0.82 | 10.5 | 36.2 |
| RTI-96 17a | F | Me | CO$_2$Me | β,β | NMe | 2.95 | 76 | 520 |
| RTI-295 | Et | I | CO$_2$Me | β,β | NMe | 21.3 | 2.96 | 1349 |
| RTI-353 (EINT) | Et | I | CO$_2$Me | β,β | NH | 331 | 0.69 | 148 |
| RTI-279 | Me | I | CO$_2$Me | β,β | NH | 5.98 | 1.06 | 74.3 |
| RTI-280 | Me | I | CO$_2$Me | β,β | NMe | 3.12 | 6.81 | 484 |
| Meltzer | catechol | catechol | CO$_2$Me | β,β | NMe | >100 | ? | ? |
| Meltzer | OAc | OAc | CO$_2$Me | β,β | NMe | ? | ? | ? |
* $^ɑ$as ·HCl (salt)
* $^b$as ·HCl·2 H$_2$O (salt)
* $^c$Singh gives the reverse value with respect to i.e. 1,329 for NET & 320 for 5-HT
Para-meta-substituted 2β-carbomethoxy-3α-(4′-substituted phenyl)tropanes :
| Short Name (S. Singh) | R$^2$ | R$^1$ | DA | 5HT | NE | Selectivity 5-HTT/DAT | Selectivity NET/DAT |
| meta-fluorophenyltropane 16a | F | H | 23 ± 7.8 | - | - | - | - |
| meta-chlorophenyltropane 16b | Cl | H | 10.6 ± 1.8 | - | - | - | - |
| meta-bromophenyltropane 16c | Br | H | 7.93 ± 0.08$^ɑ$ | - | - | - | - |
| meta-iodophenyltropane 16d | I | H | 26.1 ± 1.7 | - | - | - | - |
| meta-tributylstannylphenyltropane 16e | SnBu$_3$ | H | 1100 ± 170 | - | - | - | - |
| meta-ethynylphenyltropane | C≡CH | H | - | - | - | - | - |
| meta-methyl-para-fluorophenyltropane RTI-96 17a | CH$_3$ | F | 2.95 ± 0.58 | - | - | - | - |
| meta-methyl-para-chlorophenyltropane RTI-112$^c$ 17b | CH$_3$ | Cl | 0.81 ± 0.05 | 10.5 ± 0.05 | 36.2 ± 1.0 | 13.0 | 44.7 |
| meta-para-dichlorophenyltropane RTI-111$^b$ Dichloropane 17c | Cl | Cl | 0.79 ± 0.08$^b$ | 3.13 ± 0.36$^b$ | 18.0 ± 0.8 17.96 ± 0.85$^{'b'd}$ | 4.0$^b$ | 22.8$^b$ |
| meta-bromo-para-aminophenyltropane RTI-97 17d | Br | NH$_2$ | 3.91 ± 0.59 | 181 | 282 | 46.2 | 72.1 |
| meta-iodo-para-aminophenyltropane RTI-88 17e | I | NH$_2$ | 1.35 ± 0.11 | 120 ± 4 | 1329 ± 124 | 88.9 | 984 |
| meta-iodo-para-azidophenyltropane 17f | I | N$_3$ | 4.93 ± 0.32 | - | - | - | - |
* $^ɑ$IC$_{50}$ determined in Cynomolgous monkey caudate-putamen
* $^b$as ·HCl (salt)
* $^c$as ·HCl·2 H$_2$O (salt)
* $^d$NE$_N$
3β-(4-alkylthio, -methylsulfinyl, and -methylsulfonylphenyl)tropanes :
| Compound | R | X | $_n$ | Inhibition of [$^3$H]WIN 35,428 @ DAT IC$_{50}$ (nM) | Inhibition of [$^3$H]Paroxetine @ 5-HTT K$_i$ (nM) | Inhibition of [$^3$H]Nisoxetine @ NET K$_i$ (nM) | NET/DAT (uptake ratio) | NET/5-HTT (uptake ratio) |
| Cocaine | Des-thio/sulfinyl/sulfonyl H | H | Desmethyl 0 | 89.1 | 95 | 1990 | 22 | 21 |
| para-methoxyphenyltropane Singh: 11i | Des-thio/sulfinyl/sulfonyl OCH$_3$ | H | 0 | 6.5 ± 1.3 | 4.3 ± 0.5 | 1110 ± 64 | 171 | 258 |
| 7a | CH$_3$ | H | 0 | 9 ± 3 | 0.7 ± 0.2 | 220 ± 10 | 24 | 314 |
| 7b | C$_2$H$_5$ | H | 0 | 232 ± 34 | 4.5 ± 0.5 | 1170 ± 300 | 5 | 260 |
| 7c | CH(CH$_3$)$_2$ | H | 0 | 16 ± 2 | 23 ± 2 | 129 ± 2 | 8 | 7 |
| 7d | CF$_3$ | H | 0 | 200 ± 70 | 8 ± 2 | 1900 ± 300 | 10 | 238 |
| 7e | CH$_3$ | Br | 0 | 10.1 ± 1 | 0.6 ± 0.2 | 121 ± 12 | 12 | 202 |
| 7f | CH$_3$ | Br | 1 | 76 ± 18 | 3.2 ± 0.4 | 690 ± 80 | 9 | 216 |
| 7g | CH$_3$ | H | 1 | 91 ± 16 | 4.3 ± 0.6 | 515 ± 60 | 6 | 120 |
| 7h | CH$_3$ | H | 2 | >10,000 | 208 ± 45 | >10,000 | 1 | 48 |

### (2′,4′-Disubstituted phenyl)-tropanes

Ortho-para-substituted (2′,4′-disubstituted phenyltropanes) :
| Compound structure | Trivial IUPAC (non-systematic) Name | R$^2$ ortho | R$^1$ para | DA | 5HT | NE | Selectivity 5-HTT/DAT | Selectivity NET/DAT |
| | ortho,para-dinitrophenyltropane | NO$_2$ | NO$_2$ | - | - | - | - | - |

### (3′,4′,5′-Trisubstituted para-methoxyphenyl)-tropanes

Para-meta(3′)-meta(5′)-(di-meta)-substituted 2β-carbomethoxy-(3′,4′,5′-substituted phenyl)tropanes Para-methoxy/(ethoxy)-meta-substituted phenyltropanes :
| Short Name (All compounds tested as HCl salts) | R$^2$ 3′-(meta) | R$^3$ 5′-(di-meta) | OR$^1$ 4′-(para) | DAT IC$_{50}$ [$^3$H](compound #)12 | 5-HTT K$_i$ [$^3$H]Paroxetine | NET K$_i$ [$^3$H]Nisoxetine | Selectivity NET/DAT Ratio K$_i$/IC$_{50}$ | Selectivity NET/5-HTT Ratio K$_i$/K$_i$ |
| Cocaine | - | - | - | 89.1 | 95 | 1990 | 22 | 21 |
| 6 RTI-112 | - | - | - | 0.82 ± 0.05 | 0.95 ± 0.04 | 21.8 ± 0.6 | 27 | 23 |
| 7a 11i | H | H | CH$_3$ | 6.5 ± 1.3 | 4.3 ± 0.5 | 1110 ± 64 | 171 | 258 |
| 7b | H | H | C$_2$H$_5$ | 92 ± 8 | 1.7 ± 0.4 | 1690 ± 50 | 18 | 994 |
| 7c | F | H | CH$_3$ | 16 ± 1 | 4.8 ± 0.5 | 270 ± 50 | 17 | 56 |
| 7d | Br | H | CH$_3$ | 47 ± 15 | 3.1 ± 0.1 | 160 ± 20 | 3 | 52 |
| 7f | Br | Br | CH$_3$ | 92 ± 22 | 2.9 ± 0.1 | 4100 ± 400$^ɑ$ | 45 | 1413 |
| 7e | I | H | CH$_3$ | 170 ± 60 | 3.5 ± 0.4 | 180 ± 20 | 1 | 51 |
| 7g | I | I | CH$_3$ | 1300 ± 200 | 7.5 ± 0.8 | 180 ± 20 | 4 | 667 |
$^ɑ$N=2

### (2′,4′,5′-Trisubstituted phenyl)-tropanes

Ortho-para(4′)-meta(5′)-trisubstituted 2β-carbomethoxy-(2′,4′,5′-substituted phenyl)tropanes :
| Structure | Short Name | R$^1$ 2′-(ortho) | R$^2$ 4′-(para) | R$^3$ 5′-(meta) | DAT | 5-HTT | NET | Selectivity NET/DAT Ratio | Selectivity NET/5-HTT Ratio |
| | para-ethyl-ortho, meta-diiodophenyltropane | iodo | ethyl | iodo | — | — | — | — | — |

## 2-Carbmethoxy modified (replaced/substituted)
### General 2-carbmethoxy modifications
#### 2β-substitutions of p-methoxy-phenyltropanes

Para-OCH$_3$-(3β-(4-Methoxyphenyl)tropane-2β-carboxylic acid ester analogues :
| Short Name (All compounds tested as HCl salts) | CO$_2$R (2β-substituted) (compound 9 is 2β=R) | DAT IC$_{50}$ [$^3$H](compound #)12 | 5-HTT K$_i$ [$^3$H]Paroxetine | NET K$_i$ [$^3$H]Nisoxetine | Selectivity NET/DAT Ratio K$_i$/IC$_{50}$ | Selectivity NET/5-HTT Ratio K$_i$/K$_i$ |
| 7a 11i | CH$_3$ | 6.5 ± 1.3 | 4.3 ± 0.5 | 1110 ± 64 | 171 | 258 |
| 8a | (CH$_3$)$_2$CH | 14 ± 3 | 135 ± 35 | 2010 ± 200 | 144 | 15 |
| 8b | cyclopropane | 6.0 ± 2 | 29 ± 3 | 1230 ± 140 | 205 | 42 |
| 8c | cyclobutane | 13 ± 3 | 100 ± 8 | >3000 | 231 | 30 |
| 8d | O$_2$N...1,4-xylene...(CH$_2$)$_2$ | 42 ± 8 | 2.9 ± 0.2 | 330 ± 20 | 8 | 114 |
| 8e | H$_2$N...1,4-xylene...(CH$_2$)$_2$ | 7.0 ± 2 | 8.3 ± 0.4 | 2200 ± 300$^ɑ$ | 314 | 265 |
| 8f | CH$_3$CONH...1,4-xylene...(CH$_2$)$_2$ | 6.0 ± 1 | 5.5 ± 0.5 | 1460 ± 30 | 243 | 265 |
| 8g | H$_2$N...2-bromo-1,4-dimethylbenzene...(CH$_2$)$_2$ | 3.3 ± 1.4 | 4.1 ± 0.6 | 1850 ± 90 | 561 | 451 |
| 8h | H$_2$N...1,3-dibromo-2,5-dimethylbenzene...(CH$_2$)$_2$ | 15 ± 6 | 2.0 ± 0.4 | 2710 ± 250$^ɑ$ | 181 | 1360 |
| 8i | H$_2$N...2-iodo-1,4-dimethylbenzene...(CH$_2$)$_2$ | 2.5 ± 0.7 | 3.5 ± 1 | 2040 ± 300$^ɑ$ | 816 | 583 |
| 8j | H$_2$N...1,3-diiodo-2,5-dimethylbenzene...(CH$_2$)$_2$ | 102 ± 15 | 1.0 ± 0.1 | 2600 ± 200$^ɑ$ | 25 | 2600 |
| 9 | 3-(4-methylphenyl)-1,2-oxazole | 18 ± 6 | 860 ± 170 | >3000 | 167 | 3 |
$^ɑ$N=2

#### 2β-carboxy side-chained (p-chloro/iodo/methyl) phenyltropanes

Multi-substituted structures of 2β-ester-3β-phenyltropanes :
| Short Name (S. Singh) | R | X | IC$_{50}$ (nM) DAT [$^3$H]WIN 35428 | IC$_{50}$ (nM) 5-HTT [$^3$H]paroxetine | IC$_{50}$ (nM) NET [$^3$H]nisoxetine | Selectivity 5-HTT/DAT | Selectivity NET/DAT |
| 23a | CH(CH$_3$)$_2$ | H | 85.1 ± 2.5 | 23121 ± 3976 | 32047 ± 1491 | 272 | 376 |
| 23b | C$_6$H$_5$ | H | 76.7 ± 3.6 | 106149 ± 7256 | 19262 ± 593 | 1384 | 251 |
| 24a | CH(CH$_3$)$_2$ | Cl | 1.4 ± 0.13 6.04 ± 0.31$^ɑ$ | 1400 ± 7 128 ± 15$^b$ | 778 ± 21 250 ± 0.9$^c$ | 1000 21.2$^d$ | 556 41.4$^e$ |
| 24b | cyclopropyl | Cl | 0.96 ± 0.10 | 168 ± 1.8 | 235 ± 8.39 | 175 | 245 |
| 24c | C$_6$H$_5$ | Cl | 1.99 ± 0.05 5.25 ± 0.76$^ɑ$ | 2340 ± 27 390 ± 34$^b$ | 2960 ± 220 242 ± 30$^c$ | 1176 74.3$^d$ | 1.3 41.6$^e$ |
| 24d | C$_6$H$_4$-4-I | Cl | 32.6 ± 3.9 | 1227 ± 176 | 967.6 ± 26.3 | 37.6 | 29.7 |
| 24e | C$_6$H$_4$-3-CH$_3$ | Cl | 9.37 ± 0.52 | 2153 ± 143 | 2744 ± 140 | 230 | 293 |
| 24f | C$_6$H$_4$-4-CH$_3$ | Cl | 27.4 ± 1.5 | 1203 ± 42 | 1277 ± 118 | 43.9 | 46.6 |
| 24g | C$_6$H$_4$-2-CH$_3$ | Cl | 3.91 ± 0.23 | 3772 ± 384 | 4783 ± 387 | 965 | 1223 |
| 24h | C$_6$H$_4$-4-Cl | Cl | 55 ± 2.3 | 16914 ± 1056 | 4883 ± 288 | 307 | 88.8 |
| 24i | C$_6$H$_4$-4-OCH$_3$ | Cl | 71 ± 5.6 | 19689 ± 1843 | 1522 ± 94 | 277 | 21.4 |
| 24j | (CH$_2$)$_2$C$_6$H$_4$-4-NO$_2$ | Cl | 2.71 ± 0.13 | - | - | - | - |
| 24k | (CH)$_2$C$_6$H$_4$-4-NH$_2$ | Cl | 2.16 ± 0.25 | - | - | - | - |
| 24l | (CH$_2$)$_2$C$_6$H$_3$-3-I-4-NH$_2$ | Cl | 2.51 ± 0.25 | - | - | - | - |
| 24m | (CH$_2$)$_2$C$_6$H$_3$-3-I-4-N$_3$ | Cl | 14.5 ± 0.94 | - | - | - | - |
| 24n | (CH$_2$)$_2$C$_6$H$_4$-4-N$_3$ | Cl | 6.17 ± 0.57 | - | - | - | - |
| 24o | (CH$_2$)$_2$C$_6$H$_4$-4-NCS | Cl | 5.3 ± 0.6 | - | - | - | - |
| 24p | (CH$_2$)$_2$C$_6$H$_4$-4-NHCOCH$_2$Br | Cl | 1.73 ± 0.06 | - | - | - | - |
| 25a | CH(CH$_3$)$_2$ | I | 0.43 ± 0.05 2.79 ± 0.13$^ɑ$ | 66.8 ± 6.53 12.5 ± 1.0$^b$ | 285 ± 7.6 41.2 ± 3.0$^c$ | 155 4.5$^d$ | 663 14.8$^e$ |
| 25b | cyclopropyl | I | 0.61 ± 0.08 | 15.5 ± 0.72 | 102 ± 11 | 25.4 | 167 |
| 25c | C$_6$H$_5$ | I | 1.51 ± 0.34 6.85 ± 0.93$^ɑ$ | 184 ± 22 51.6 ± 6.2$^b$ | 3791 ± 149 32.7 ± 4.4$^c$ | 122 7.5$^d$ | 2510 4.8$^e$ |
| 26a | CH(CH$_3$)$_2$ | CH$_3$ | 6.45 ± 0.85 15.3 ± 2.08$^ɑ$ | 6090 ± 488 917 ± 54$^b$ | 1926 ± 38 73.4 ± 11.6$^c$ | 944 59.9$^d$ | 299 4.8$^e$ |
| 26b | CH(C$_2$H$_5$)$_2$ | CH$_3$ | 19.1 ± 1 | 4499 ± 557 | 3444 ± 44 | 235 | 180 |
| 26c | cyclopropyl | CH$_3$ | 17.8 ± 0.76 | 485 ± 21 | 2628 ± 252 | 27.2 | 148 |
| 26d | cyclobutyl | CH$_3$ | 3.74 ± 0.52 | 2019 ± 133 | 4738 ± 322 | 540 | 1267 |
| 26e | cyclopentyl | CH$_3$ | 1.68 ± 0.14 | 1066 ± 109 | 644 ± 28 | 634 | 383 |
| 26f | C$_6$H$_5$ | CH$_3$ | 3.27 ± 0.06 9.13 ± 0.79$^ɑ$ | 24500 ± 1526 1537 ± 101$^b$ | 5830 ± 370 277 ± 23$^c$ | 7492 168$^d$ | 1783 30.3$^e$ |
| 26g | C$_6$H$_4$-3-CH$_3$ | CH$_3$ | 8.19 ± 0.90 | 5237 ± 453 | 2136 ± 208 | 639 | 261 |
| 26h | C$_6$H$_4$-4-CH$_3$ | CH$_3$ | 81.2 ± 16 | 15954 ± 614 | 4096 ± 121 | 196 | 50.4 |
| 26i | C$_6$H$_4$-2-CH$_3$ | CH$_3$ | 23.2 ± 0.97 | 11040 ± 504 | 25695 ± 1394 | 476 | 1107 |
| 26j | C$_6$H$_4$-4-Cl | CH$_3$ | 117 ± 7.9 | 42761 ± 2399 | 9519 ± 864 | 365 | 81.3 |
| 26k | C$_6$H$_4$-4-OCH$_3$ | CH$_3$ | 95.6 ± 8.8 | 82316 ± 7852 | 3151 ± 282 | 861 | 33.0 |
* $^ɑ$Ki value for displacement of [$^3$H]DA uptake.
* $^b$Ki value for displacement of [$^3$H]5-HT uptake.
* $^c$Ki value for displacement of [$^3$H]NE uptake.
* $^d$[$^3$H]5-HT uptake to [$^3$H]DA uptake ratio.
* $^e$[$^3$H]NE uptake to [$^3$H]DA uptake ratio.

### Carboxyaryl

| Compound | X | 2 Position | config | 8 | DA | 5-HT | NE |
| RTI-122 | I | -CO$_2$Ph | β,β | NMe | 1.50 | 184 | 3,791 |
| RTI-113 | Cl | -CO$_2$Ph | β,β | NMe | 1.98 | 2,336 | 2,955 |
| RTI-277 | NO$_2$ | -CO$_2$Ph | β,β | NMe | 5.94 | 2,910 | 5,695 |
| RTI-120 [recheck] | Me | -CO$_2$Ph | β,β | NMe | 3.26 | 24,471 | 5,833 |
| RTI-116 | Cl | -CO$_2$(p-C$_6$H$_4$I) | β,β | NMe | 33 | 1,227 | 968 |
| RTI-203 | Cl | CO$_2$(m-C$_6$H$_4$Me) | β,β | NMe | 9.37 | 2153 | 2744 |
| RTI-204 | Cl | -CO$_2$(o-C$_6$H$_4$Me) | β,β | NMe | 3.91 | 3,772 | 4,783 |
| RTI-205 | Me | -CO$_2$(m-C$_6$H$_4$Me) | β,β | NMe | 8.19 | 5,237 | 2,137 |
| RTI-206 | Cl | -CO$_2$(p-C$_6$H$_4$Me) | β,β | NMe | 27.4 | 1,203 | 1,278 |

#### 2-Phenyl-3-Phenyltropanes

2-Phenyl-3-phenyltropane binding affinities and inhibition of DA & 5-HT Uptake :
| Short Name (S. Singh) | Stereochemistry | X (para) | DAT [$^3$H]WIN 35428 IC$_{50}$ (nM) | DAT [$^3$H]Mazindol K$_i$ (nM) | 5-HTT [$^3$H]Paroxetine IC$_{50}$ (nM) | [$^3$H]DA uptake K$_i$ (nM) | [$^3$H]5-HT uptake K$_i$ (nM) | Selectivity [$^3$H]5-HT/[$^3$H]DA |
| Cocaine | (2β,3β) | (H) | 89 ± 4.8 | 281 | 1050 ± 89 | 423 | 155 | 0.4 |
| 67a | 2β,3β | H | 12.6 ± 1.8 | 14.9 | 21000 ± 3320 | 28.9 | 1100 | 38.1 |
| 67b | 2β,3α | H | - | 13.8 | - | 11.7 | 753 | 64.3 |
| 67c | 2α,3α | H | 690 ± 37 | - | 41300 ± 5300 | - | - | - |
| 68 | 2β,3α | F | - | 6.00 | - | 4.58 | 122 | 26.6 |
| 69a | 2β,3β | CH$_3$ | 1.96 ± 0.08 | 2.58 | 11000 ± 83 | 2.87 | 73.8 | 25.7 |
| 69b | 2β,3α | CH$_3$ | - | 2.87 | - | 4.16 | 287 | 69.0 |
| 69c | 2α,3α | CH$_3$ | 429 ± 59 | - | 15800 ± 3740 | - | - | - |

### Carboxyalkyl

| Code | X | 2 Position | config | 8 | DA | 5-HT | NE |
| RTI-77 | Cl | CH$_2$C$_2$(3-iodo-p-anilino) | β,β | NMe | 2.51 | — | 2247 |
| RTI-121 IPCIT | I | -CO$_2$Pr$^i$ | β,β | NMe | 0.43 | 66.8 | 285 |
| RTI-153 | I | -CO$_2$Pr$^i$ | β,β | NH | 1.06 | 3.59 | 132 |
| RTI-191 | I | -CO$_2$Pr$^{cyc}$ | β,β | NMe | 0.61 | 15.5 | 102 |
| RTI-114 | Cl | -CO$_2$Pr$^i$ | β,β | NMe | 1.40 | 1,404 | 778 |
| RTI-278 | NO$_2$ | -CO$_2$Pr$^i$ | β,β | NMe | 8.14 | 2,147 | 4,095 |
| RTI-190 | Cl | -CO$_2$Pr$^{cyc}$ | β,β | NMe | 0.96 | 168 | 235 |
| RTI-193 | Me | -CO$_2$Pr$^{cyc}$ | β,β | NMe | 1.68 | 1,066 | 644 |
| RTI-117 | Me | -CO$_2$Pr$^i$ | β,β | NMe | 6.45 | 6,090 | 1,926 |
| RTI-150 | Me | -CO$_2$Bu$^{cyc}$ | β,β | NMe | 3.74 | 2,020 | 4,738 |
| RTI-127 | Me | -CO$_2$C(H)Et$_2$ | β,β | NMe | 19 | 4500 | 3444 |
| RTI-338 | ethyl | -CO$_2$C$_2$Ph | β,β | NMe | 1104 | 7.41 | 3366 |
Use of a cyclopropyl ester appears to enable better MAT retention than does the choice of isopropyl ester.
Use of a $^{cyc}$Bu resulted in greater DAT selectivity than did the $^{cyc}$Pr homologue.

#### 2-Alkyl Esters & Ethers
##### Esters (2-Alkyl)

2β-Alkyl Ester Phenyltropanes :
| Short Name (S. Singh) | 2β=R | K$_i$ (nM) DAT [$^3$H]WIN 35428 | IC$_{50}$ (nM) [$^3$H]DA uptake | Selectivity uptake/binding |
| 59a | CH=CHCO$_2$CH$_3$ | 22 ± 2 | 123 ± 65 | 5.6 |
| 59b | CH$_2$CH$_2$CO$_2$CH$_3$ | 23 ± 2 | 166 ± 68 | 7.2 |
| 59c | (CH$_2$)$_2$CH=CHCO$_2$CH$_3$ | 20 ± 2 | 203 ± 77 | 10.1 |
| 59d | (CH$_{22}$)$_4$CO$_2$CH$_3$ | 30 ± 2 | 130 ± 7 | 4.3 |
| 59e | CH=CHCH$_2$OH | 26 ± 3 | 159 ± 43 | 6.1 |
| 59f | CH$_2$CH$_2$CH$_2$OH | 11 ± 1 | 64 ± 32 | 5.8 |
| 59g | CH$_2$CH$_2$COC$_6$H$_5$ | 28 ± 2 | 47 ± 15 | 1.7 |

##### Ethers (2-Alkyl)

2-Alkyl Ether Phenyltropanes :
| Short Name (S. Singh) | Stereochemistry | DAT [$^3$H]WIN 35428 IC$_{50}$ (nM) | 5-HTT [$^3$H]Paroxetine IC$_{50}$ (nM) | NET [$^3$H]Nisoxetine IC$_{50}$ (nM) | Selectivity 5-HTT/DAT | Selectivity NET/DAT |
| Paroxetine | | 623 ± 25 | 0.28 ± 0.02 | 535 ± 15 | 0.0004 | 0.8 |
| R-60a | 2β,3β | 308 ± 20 | 294 ± 18 | 5300 ± 450 | 0.9 | 17.2 |
| R-60b | 2α,3β | 172 ± 8.8 | 52.9 ± 3.6 | 26600 ± 1200 | 0.3 | 155 |
| R-60c | 2β,3α | 3.01 ± 0.2 | 42.2 ± 16 | 123 ± 9.5 | 14.1 | 40.9 |
| S-60d | 2β,3β | 1050 ± 45 | 88.1 ± 2.8 | 27600 ± 1100 | 0.08 | 26.3 |
| S-60e | 2α,3β | 1500 ± 74 | 447 ± 47 | 2916 ± 1950 | 0.3 | 1.9 |
| S-60f | 2β,3α | 298 ± 17 | 178 ± 13 | 12400 ± 720 | 0.6 | 41.6 |

### Carboxamides

U.S. patent 5,736,123
| Code (S. Singh #) | X | 2 Position | config | 8 | DA [$^3$H]WIN 35428 (IC$_{50}$ nM) | NE [$^3$H]nisoxetine | 5-HT [$^3$H]paroxetine (IC$_{50}$ nM) | Selectivity 5-HTT/DAT | Selectivity NET/DAT |
| RTI-106 27b | Cl | CON(H)Me | β,β | NMe | 12.4 ± 1.17 | 1584 ± 62 | 1313 ± 46 | 106 | 128 |
| RTI-118 27a | Cl | CONH$_2$ | β,β | NMe | 11.5 ± 1.6 | 4270 ± 359 | 1621 ± 110 | 141 | 371 |
| RTI-222 29d | Me | morpholinyl | β,β | NMe | 11.7 ± 0.87 | 23601 ± 1156 | >100K | >8547 | 2017 |
| RTI-129 27e | Cl | CONMe$_2$ | β,β | NMe | 1.38 ± 0.1 | 942 ± 48 | 1079 ± 102 | 792 | 683 |
| RTI-146 27d | Cl | CONHCH$_2$OH | β,β | NMe | 2.05 ± 0.23 | 144 ± 3 | 97.8 ± 10 | 47.7 | 70.2 |
| RTI-147 27i | Cl | CON(CH$_2$)$_4$ | β,β | NMe | 1.38 ± 0.03 | 3,950 ± 72 | 12400 ± 1207 | 8985 | 2862 |
| RTI-156 | Cl | CON(CH$_2$)$_5$ | β,β | NMe | 6.61 | 5832 | 3468 | | |
| RTI-170 | Cl | CON(H)CH$_2$C≡CH | β,β | NMe | 16.5 | 1839 | 4827 | | |
| RTI-172 | Cl | CON(H)NH$_2$ | β,β | NMe | 44.1 | 3914 | 3815 | | |
| RTI-174 | Cl | CONHCOMe | β,β | NMe | 158 | >43K | >125K | | |
| RTI-182 | Cl | CONHCH$_2$COPh | β,β | NMe | 7.79 | 1722 | 827 | | |
| RTI-183✲ 27 g | Cl | CON(OMe)Me | β,β | NMe | 0.85 ± 0.06 | 549 ± 18.5 | 724 ± 94 | 852 | 646 |
| RTI-186 29c | Me | CON(OMe)Me | β,β | NMe | 2.55 ± 0.43 | 422 ± 26 | 3402 ± 353 | 1334 | 165 |
| RTI-198 27h | Cl | CON(CH$_2$)$_3$ | β,β | NMe | 6.57 ± 0.67 | 990 ± 4.8 | 814 ± 57 | 124 | 151 |
| RTI-196 27c | Cl | CONHOMe | β,β | NMe | 10.7 ± 1.25 | 9907 ± 632 | 43700 ± 1960 | 4084 | 926 |
| RTI-201 | Cl | CONHNHCOPh | β,β | NMe | 91.8 | >20K | >48K | | |
| RTI-208 27j | Cl | CONO(CH$_2$)$_3$ | β,β | NMe | 1.47 ± 0.13 | 1083 ± 76 | 2470 ± 56 | 1680 | 737 |
| RTI-214 27l | Cl | CON(-CH$_2$CH$_2$-)$_2$O | β,β | NMe | 2.90 ± 0.3 | 8545 ± 206 | 88769 ± 1855 | 30610 | 2946 |
| RTI-215 27f | Cl | CONEt$_2$ | β,β | NMe | 5.48 ± 0.19 | 5532 ± 299 | 9433 ± 770 | 1721 | 1009 |
| RTI-217 | Cl | CONH(m-C$_6$H$_4$OH) | β,β | NMe | 4.78 | >30K | >16K | | |
| RTI-218✲ | Cl | CON(Me)OMe | β,β | NMe | 1.19 | 520 | 1911 | | |
| RTI-226 27 m | Cl | CONMePh | β,β | NMe | 45.5 ± 3 | 2202 ± 495 | 23610 ± 2128 | 519 | 48.4 |
| RTI-227 | I | CONO(CH$_2$)$_3$ | β,β | NMe | 0.75 | 446 | 230 | | |
| RTI-229 28a | I | CON(CH$_2$)$_4$ | β,β | NMe | 0.37 ± 0.04 | 991 ± 21 | 1728 ± 39 | 4670 | 2678 |
| 27k | | | | | 6.95 ± 1.21 | 1752 ± 202 | 3470 ± 226 | 499 | 252 |
| 28b | | | | | 1.08 ± 0.15 | 103 ± 6.2 | 73.9 ± 8.1 | 68.4 | 95.4 |
| 28c | | | | | 0.75 ± 0.02 | 357 ± 42 | 130 ± 15.8 | 173 | 476 |
| 29a | | | | | 41.8 ± 2.45 | 4398 ± 271 | 6371 ± 374 | 152 | 105 |
| 29b | | | | | 24.7 ± 1.93 | 6222 ± 729 | 33928 ± 2192 | 1374 | 252 |
✲RTI-183 and RTI-218 suggest possible copy-error, seeing as "CON(OMe)Me" & "CON(Me)OMe" difference between methyl & methoxy render as the same.
2β-Carboxamide-3β-Phenyltropanes :
| Short Name (S. Singh) | R | X | IC$_{50}$ (nM) DAT [$^3$H]WIN 35428 | IC$_{50}$ (nM) 5-HTT [$^3$H]Paroxetine | IC$_{50}$ (nM) NET [$^3$H]Nisoxetine | Selectivity 5-HTT/DAT | Selectivity NET/DAT |
| 29a | NH$_2$ | CH$_3$ | 41.8 ± 2.45 | 6371 ± 374 | 4398 ± 271 | 152 | 105 |
| 29b | N(CH$_2$CH$_3$)$_2$ | CH$_3$ | 24.7 ± 1.93 | 33928 ± 2192 | 6222 ± 729 | 1374 | 252 |
| 29c RTI-186 | N(OCH$_3$)CH$_3$ | CH$_3$ | 2.55 ± 0.43 | 3402 ± 353 | 422 ± 26 | 1334 | 165 |
| 29d RTI-222 | 4-morpholine | CH$_3$ | 11.7 ± 0.87 | >100000 | 23601 ± 1156 | >8547 | 2017 |

#### Carboxamide linked phenyltropanes dimers

Dimers of phenyltropanes, connected in their dual form using the C2 locant as altered toward a carboxamide structural configuring (in contrast and away from the usual inherent ecgonine carbmethoxy), as per Frank Ivy Carroll's patent inclusive of such chemical compounds, possibly so patented due to being actively delayed pro-drugs in vivo.

### Heterocycles

These heterocycles are sometimes referred to as the "bioisosteric equivalent" of the simpler esters from which they are derived. A potential disadvantage of leaving the ββ-ester unreacted is that in addition to being hydrolyzable, it can also epimerize to the energetically more favorable trans configuration. This can happen to cocaine also.
Several of the oxadiazoles contain the same number and types of heteroatoms, while their respective binding potencies display 8×-15× difference. A finding that would not be accounted for by their affinity originating from hydrogen bonding.
To explore the possibility of electrostatic interactions, the use of molecular electrostatic potentials (MEP) were employed with model compound 34 (replacing the phenyltropane moiety with a methyl group). Focusing on the vicinity of the atoms @ positions A—C, the minima of electrostatic potential near atom position A (ΔV$_{min}$(A)), calculated with semi-empirical (AM1) quantum mechanics computations (superimposing the heterocyclic and phenyl rings to ascertain the least in the way of steric and conformational discrepancies) found a correlation between affinity @ DAT and ΔV$_{min}$(A): wherein the values for the latter for 32c = 0, 32g = -4, 32h = -50 & 32i = -63 kcal/mol.
In contrast to this trend, it is understood that an increasingly negative ΔV$_{min}$ is correlated with an increase of strength in hydrogen bonding, which is the opposing trend for the above; this indicates that the 2β-substituents (at least for the heterocyclic class) are dominated by electrostatic factors for binding in-the-stead of the presumptive hydrogen bonding model for this substituent of the cocaine-like binding ligand.

#### 3-Substituted-isoxazol-5-yl

N-methylphenyltropanes with 1R β,β stereochemistry. :
| Code (S.S. #) | X | R | DA | NE | 5HT |
| RTI-165 | Cl | 3-methylisoxazol-5-yl | 0.59 | 181 | 572 |
| RTI-171 | Me | 3-methylisoxazol-5-yl | 0.93 | 254 | 3818 |
| RTI-180 | I | 3-methylisoxazol-5-yl | 0.73 | 67.9 | 36.4 |
| RTI-177 β-CPPIT 32g | Cl | 3-phenylisoxazol-5-yl | 1.28 ± 0.18 | 504 ± 29 | 2420 ± 136 |
| RTI-176 | Me | 3-phenylisoxazol-5-yl | 1.58 | 398 | 5110 |
| RTI-181 | I | 3-phenylisoxazol-5-yl | 2.57 | 868 | 100 |
| RTI-184 | H | methyl | 43.3 | — | 6208 |
| RTI-185 | H | Ph | 285 | — | >12K |
| RTI-334 | Cl | 3-ethylisoxazol-5-yl | 0.50 | 120 | 3086 |
| RTI-335 | Cl | isopropyl | 1.19 | 954 | 2318 |
| RTI-336 | Cl | 3-(4-methylphenyl)isoxazol-5-yl | 4.09 | 1714 | 5741 |
| RTI-337 | Cl | 3-t-butyl-isoxazol-5-yl | 7.31 | 6321 | 37K |
| RTI-345 | Cl | p-chlorophenyl | 6.42 | 5290 | >76K |
| RTI-346 | Cl | p-anisyl | 1.57 | 762 | 5880 |
| RTI-347 | Cl | p-fluorophenyl | 1.86 | 918 | 7257 |
| RTI-354 | Me | 3-ethylisoxazol-5-yl | 1.62 | 299 | 6400 |
| RTI-366 | Me | R = isopropyl | 4.5 | 2523 (1550) | 42,900 (3900) |
| RTI-371 | Me | p-chlorophenyl | 8.74 | >100K (60,200) | >100K (9090) |
| RTI-386 | Me | p-anisyl | 3.93 | 756 (450) | 4027 (380) |
| RTI-387 | Me | p-fluorophenyl | 6.45 | 917 (546) | >100K (9400) |

#### 3-Substituted-1,2,4-oxadiazole

Heterocyclic (N-methyl)phenyltropanes with 1R stereochemistry. :
| Code (Singh's #) | X | R | DAT (IC$_{50}$ nM) displacement of [$^3$H]WIN 35428 | NET (IC$_{50}$ nM) [$^3$H]nisoxetine | 5-HTT (IC$_{50}$ nM) [$^3$H]paroxetine | Selectivity 5-HTT/DAT | Selectivity NET/DAT |
| ααRTI-87 | H | 3-methyl-1,2,4-oxadiazole | 204 | 36K | 30K | | |
| βαRTI-119 | H | 3-methyl-1,2,4-oxadiazole | 167 | 7K | 41K | | |
| αβRTI-124 | H | 3-methyl-1,2,4-oxadiazole | 1028 | 71K | 33K | | |
| RTI-125 (32a) | Cl | 3-methyl-1,2,4-oxadiazole | 4.05 ± 0.57 | 363 ± 36 | 2584 ± 800 | 637 | 89.6 |
| ββRTI-126 (31) | H | 3-methyl-1,2,4-oxadiazole | 100 ± 6 | 7876 ± 551 | 3824 ± 420 | 38.3 | 788 |
| RTI-130 (32c) | Cl | 3-phenyl-1,2,4-oxadiazole | 1.62 ± 0.02 | 245 ± 13 | 195 ± 5 | 120 | 151 |
| RTI-141 (32d) | Cl | 3-(p-anisyl)-1,2,4-oxadiazole | 1.81 ± 0.19 | 835 ± 8 | 337 ± 40 | 186 | 461 |
| RTI-143 (32e) | Cl | 3-(p-chlorophenyl)-1,2,4-oxadiazole | 4.06 ± 0.22 | 40270 ± 180 (4069) | 404 ± 56 | 99.5 | 9919 |
| RTI-144 (32f) | Cl | 3-(p-bromophenyl)-1,2,4-oxadiazole | 3.44 ± 0.36 | 1825 ± 170 | 106 ± 10 | 30.8 | 532 |
| βRTI-151 (33) | Me | 3-phenyl-1,2,4-oxadiazole | 2.33 ± 0.26 | 60 ± 2 | 1074 ± 130 | 459 | 25.7 |
| αRTI-152 | Me | 3-phenyl-1,2,4-oxadiazole | 494 | — | 1995 | | |
| RTI-154 (32b) | Cl | 3-isopropyl-1,2,4-oxadiazole | 6.00 ± 0.55 | 135 ± 13 | 3460 ± 250 | 577 | 22.5 |
| RTI-155 | Cl | 3-cyclopropyl-1,2,4-oxadiazole | 3.41 | 177 | 4362 | | |
N-methylphenyltropanes with 1R β,β stereochemistry. :
| Code | X | 2 Group | DAT (IC$_{50}$ nM) displacement of [$^3$H]WIN 35428 | NET (IC$_{50}$ nM) displacement of [$^3$H]nisoxetine | 5-HTT (IC$_{50}$ nM) displacement of [$^3$H]paroxetine | Selectivity 5-HTT/DAT | Selectivity NET/DAT |
| RTI-157 | Me | tetrazole | 1557 | >37K | >43K | | |
| RTI-163 | Cl | tetrazole | 911 | — | 5456 | | |
| RTI-178 | Me | 5-phenyl-oxazol-2-yl | 35.4 | 677 | 1699 | | |
| RTI-188 | Cl | 5-phenyl-1,3,4-oxadiazol-2-yl | 12.6 | 930 | 3304 | | |
| RTI-189 (32i) | Cl | 5-phenyl-oxazol-2-yl | 19.7 ± 1.98 | 496 ± 42 | 1120 ± 107 | 56.8 | 25.5 |
| RTI-194 | Me | 5-methyl-1,3,4-oxadiazol-2-yl | 4.45 | 253 | 4885 | | |
| RTI-195 | Me | 5-phenyl-1,3,4-oxadiazol-2-yl | 47.5 | 1310 | >22,000 | | |
| RTI-199 | Me | 5-phenyl-1,3,4-thiadiazol-2-yl | 35.9 | >24,000 | >51,000 | | |
| RTI-200 | Cl | 5-phenyl-1,3,4-thiadiazol-2-yl | 15.3 | 4142 | >18,000 | | |
| RTI-202 | Cl | benzothiazol-2-yl | 1.37 | 403 | 1119 | | |
| RTI-219 | Cl | 5-phenylthiazol-2-yl | 5.71 | 8516 | 10,342 | | |
| RTI-262 | Cl | | 188.2 ± 5.01 | 595.25 ± 5738 | 5207 ± 488 | 316 | 28 |
| RTI-370 | Me | 3-(p-cresyl)isoxazol-5-yl | 8.74 | 6980 | >100K | | |
| RTI-371 | Cl | 3-(p-chlorophenyl)isoxazol-5-yl | 13 | >100K | >100K | | |
| RTI-436 | Me | -CH=CHPh | 3.09 | 1960 (1181) | 335 (31) | | |
| RTI-470 | Cl | o-Cl-benzothiazol-2-yl | 0.094 | 1590 (994) | 1080 (98) | | |
| RTI-451 | Me | benzothiazol-2-yl | 1.53 | 476 (287) | 7120 (647) | | |
| 32g | | | 1.28 ± 0.18 | 504 ± 29 | 2420 ± 136 | 1891 | 394 |
| 32h | | | 12.6 ± 10.3 | 929 ± 88 | 330 ± 196 | 262 | 73.7 |
N.B There are some alternative ways of making the tetrazole ring however; C.f. the sartan drugs synthesis schemes. Bu$_3$SnN$_3$ is a milder choice of reagent than hydrogen azide (c.f. Irbesartan).

### Acyl (C2-propanoyl)

* Indolyl cf. the Tamagnan series of phenyltropanes for examples with a methylene unit spacer breaking up the indole.
| # (#) | X | Y | 2 Position | config | 8 | DA | 5-HT | NE |
| WF-23 (39n) | β-naphthyl | β-naphthyl | C(O)Et | β,β | NMe | 0.115 | 0.394 | No data |
| WF-31 PIT | -Pr$^i$ | H | C.O.Et | β,β | NMe | 615 | 54.5 | No data |
| WF-11$^✲$ PTT (39e) | Me | H | -C.O.Et | β,β | NMe | 8.2 | 131 | No data |
| WF-25 (39a) | H | H | -C.O.Et | β,β | NMe | 48.3 | 1005 | No data |
| WF-33 | 6-MeoBN | 6-MeoBN | C(O)Et | α,β | NMe | 0.13 | 2.24 | No data |
| $^✲$Compound WF-11 has been shown, under consistent exposure, to elicit a biological response opposite of cocaine i.e. tyrosine hydroxylase gene expression down-regulation (instead of up-regulation as has been observed to be the case for chronic cocaine administration) |||||||||
2β-acyl-3β-phenyltropane structures :
| S. Singh's alphanumeric assignation (name) | R$_1$ | R$_2$ | DAT [$^{125}$I]RTI-55 IC$_{50}$ (nM) | 5-HTT [$^3$H]Paroxetine K$_i$ (nM) | Selectivity 5-HTT/DAT |
| cocaine | | | 173 ± 19 | — | — |
| Troparil 11a (WIN 35065–2) | | | 98.8 ± 12.2 | — | — |
| WF-25 39a | C$_2$H$_5$ | C$_6$H$_5$ | 48.3 ± 2.8 | 1005 ± 112 | 20.8 |
| 39b | CH$_3$ | C$_6$H$_5$ | 114 ± 22 | 1364 ± 616 | 12.0 |
| 39c | C$_2$H$_5$ | C$_6$H$_4$-4-F | 15.3 ± 2.8 | 630 ± 67 | 41.2 |
| 39d | CH$_3$ | C$_6$H$_4$-4-F | 70.8 ± 13 | 857 ± 187 | 12.1 |
| WF-11 39e | C$_2$H$_5$ | C$_6$H$_4$-4-CH$_3$ | 8.2 ± 1.6 | 131 ± 1 | 16.0 |
| (+)-39e | C$_2$H$_5$ | C$_6$H$_4$-4-CH$_3$ | 4.21 ± 0.05 | 74 ± 12 | 17.6 |
| (-)-39e | C$_2$H$_5$ | C$_6$H$_4$-4-CH$_3$ | 1337 ± 122 | >10000 | — |
| 39f | CH$_3$ | C$_6$H$_4$-4-CH$_3$ | 9.8 ± 0.5 | 122 ± 22 | 12.4 |
| 39g | CH$_3$ | C$_6$H$_4$-4-C$_2$H$_5$ | 152 ± 24 | 78.2 ± 22 | 0.5 |
| 39h | C$_2$H$_5$ | C$_6$H$_4$-4-CH(CH$_3$)$_2$ | 436 ± 41 | 35.8 ± 4.4 | 0.08 |
| 39i | C$_2$H$_5$ | C$_6$H$_4$-4-C(CH$_3$)$_3$ | 2120 ± 630 | 1771 ± 474 | 0.8 |
| 39j | C$_2$H$_5$ | C$_6$H$_4$-4-C$_6$H$_5$ | 2.29 ± 1.08 | 4.31 ± 0.01 | 1.9 |
| 39k | C$_2$H$_5$ | C$_6$H$_4$-2-CH$_3$ | 1287 ± 322 | 710000 | >7.8 |
| 39l | C$_2$H$_5$ | 1-naphthyl | 5.43 ± 1.27 | 20.9 ± 2.9 | 3.8 |
| 39m | CH$_3$ | 1-naphthyl | 10.1 ± 2.2 | 25.6 ± 5.1 | 2.5 |
| WF-23 39n | C$_2$H$_5$ | 2-naphthyl | 0.115 ± 0.021 | 0.394 ± 0.074 | 3.5 |
| 39o | CH$_3$ | 2-naphthyl | 0.28 ± 0.11 | 1.06 ± 0.36 | 3.8 |
| 39p | C$_2$H$_5$ | C$_6$H$_4$-4-CH(C$_2$H$_5$)$_2$ | 270 ± 38 | 540 ± 51 | 2.0 |
| 39q | C$_2$H$_5$ | C$_6$H$_4$-4-C$_6$H$_{11}$ | 320 ± 55 | 97 ± 12 | 0.30 |
| 39r | C$_2$H$_5$ | C$_6$H$_4$-4-CH=CH$_2$ | 0.90 ± 0.34 | 3.2 ± 1.3 | 3.5 |
| 39s | C$_2$H$_5$ | C$_6$H$_4$-4-C(=CH$_2$)CH$_3$ | 7.2 ± 2.1 | 0.82 ± 0.38 | 0.1 |

#### 2β-Acyl-3β-naphthyl substituted

2β-Acyl-3β-(substituted naphthyl)-8-azabicyclo[3.2.1]octanes :
| Short Assignation (Numeric code, Davies UB) S. Singh | R | DAT [$^{125}$H]RTI-55$^ɑ$ IC$_{50}$ nM | SERT [$^3$H]paroxetine$^b$ K$_i$ nM | NET [$^3$H]nisoxetine$^c$ K$_i$ nM | potency ratio SERT/DAT | potency ratio SERT/NET |
| WF-11 (6) | 4′-Me | 8.2 ± 1.6 | 131 ± 10 | 65 ± 9.2 | 0.06 | 0.5 |
| WF-31 (7) | 4′-$^i$Pr | 436 ± 41 | 36 ± 4 | >10,000 | 12 | >250 |
| WF-23 (8) | 2-naphthalene | 0.12 ± 0.02 | 0.39 ± 0.07 | 2.9 ± 0.5 | 0.3 | 7 |
| 2β-acyl-3β-1-naphthalene (9a) | 4′-H | 5.3 ± 1.3 | 21 ± 2.9 | 49 ± 10 | 0.3 | 18 |
| (9b) | 4′-Me | 25.1 ± 0.5 | 8.99 ± 1.70 | 163 ± 36 | 3 | 18 |
| (9c) | 4′-Et | 75.1 ± 11.9 | 175 ± 25 | 4769 ± 688 | 0.7 | 27 |
| (9d) | 4′-$^i$Pr | 225 ± 36 | 136 ± 64 | >10,000 | 2 | >73.5 |
| (10a) | 6′-Et | 0.15 ± 0.04 | 0.38 ± 0.19 | 27.7 ± 9.6 | 0.4 | 74 |
| (10b) | 6′-$^i$Pr | 0.39 ± 0.04 | 1.97 ± 0.33 | no data | 0.2 | — |
| (10c$^e$) | 6′- OMe | 0.13 ± 0.04 | 2.24 ± 0.34 | no data | 0.05 | — |
| (10d) | 5′-Et, 6′-OMe | 30.8 ± 6.6 | 7.55 ± 1.57 | 3362 ± 148 | 4.1 | 445 |
| (10e) | 5′-C(Me)=CH$_2$, 6′-OMe | 45.0 ± 3.7 | 88.0 ± 13.3 | 2334 ± 378 | 0.5 | 26.5 |
| (10f) | 6′-I | 0.35 ± 0.07 | 0.37 ± 0.02 | no data | 1.0 | — |
| (10g) | 7′-I | 0.45 ± 0.05 | 0.47 ± 0.02 | no data | 0.5$^d$ | — |
| (10h) | 5′-NO$_2$, 6′-OMe | 148 ± 50 | 15 ± 1.6 | no data | 10 | — |
| (10i) | 5′-I, 6′-OMe | 1.31 ± 0.33 | 2.27 ± 0.31 | 781 ± 181 | 0.6 | 344 |
| (10j) | 5′-COMe, 6′-OMe | 12.6 ± 3.8 | 15.8 ± 1.65 | 498 ± 24 | 0.8 | 32 |
| (11a) | 2β-COCH$_3$, 1-naphthyl | 10 ± 2.2 | 26 ± 5.1 | 165 ± 40 | 0.4 | 6.3 |
| (11b) | 2α-COCH$_3$, 1-naphthyl | 97 ± 21 | 217 ± 55 | no data | 0.45 | — |
| (11c) | 2α-COCH$_2$CH$_3$, 2-naphthyl | 2.51 ± 0.82 | 16.4 ± 2.0 | 68.0 ± 10.8 | 0.15 | 4.1 |
| (11d) | 2β-COCH$_3$, 2-naphthyl | 1.27 ± 0.15 | 1.06 ± 0.36 | 4.9 ± 1.2 | 1.2 | 4.6 |
| (11e) | 2β-COCH(CH$_3$)$_2$, 2-naphthyl | 0.25 ± 0.08 | 2.08 ± 0.80 | 37.6 ± 10.5 | 0.12 | 18.1 |
| (11f) 79a | 2β-COCH$_2$CH$_3$, 2-naphthyl, N8-demethyl | 0.03 ± 0.01 | 0.23 ± 0.07 | 2.05 ± 0.9 | 0.13 | 8.9 |
| $^ɑ$ nonspecific binding was determined in the presence of 1.0 μM WF-23 (source equates WF-23 as analogue 3a, but table gives # as analogue 8) $^b$ nonspecific binding was determined in the presence of 10.0 μM fluoxetine | $^c$ nonspecific binding was determined in the presence of 1.0 μM desipramine $^d$ ratio shown as halved; a possible copy-error due to closeness to 1:1 of other indicated values $^e$ sources differ on whether C2 position acyl is alpha or beta configured |

### Ester reduction

Note: p-fluorophenyl is weaker than the others. RTI-145 is not peroxy, it is a methyl carbonate.
| Code | X | 2 Position | config | 8 | DA | 5-HT | NE |
| RTI-100 | F | -CH$_2$OH | β,β | NMe | 47 | 4741 | no data |
| RTI-101 | I | -CH$_2$OH | β,β | NMe | 2.2 | 26 | no data |
| RTI-99 | Br | -CH$_2$OH | β,β | NMe | 1.49 | 51 | no data |
| RTI-93 | Cl | -CH$_2$OH | β,β | NMe | 1.53 | 204 | 43.8 |
| RTI-105 | Cl | -CH$_2$OAc | β,β | NMe | 1.60 | 143 | 127 |
| RTI-123 | Cl | -CH$_2$OBz | β,β | NMe | 1.78 | 3.53 | 393 |
| RTI-145 | Cl | -CH$_2$OCO$_2$Me | β,β | NMe | 9.60 | 2.93 | 1.48 |

### 2-Alkane/Alkene

2-Alkane/Alkene-3-Phenyltropanes :
| Singh's # | R | X | DAT mazindol displacement | DA uptake | 5-HT Uptake | Selectivity DA uptake/DAT binding |
| 11a WIN 35062-2 | | | 89.4 | 53.7 | 186 | 0.6 |
| 11c | | | 0.83 ± 00.7 | 28.5 ± 0.9 | — | 34.3 |
| 11f | | | 5.76 | 6.92 | 23.2 | 1.2 |
| 41a | (CH$_2$)$_2$CH$_3$ | H | 12.2 | 6.89 | 86.8 | 0.6 |
| 41b | (CH$_2$)$_3$C$_6$H$_5$ | H | 16 ± 2$^a$ | 43 ± 13$^b$ | — | 2.7 |
| 42 | (CH$_2$)$_2$CH$_3$ | F | 5.28 | 1.99 | 21.7 | 0.4 |
| 43a | CH=CH$_2$ | Cl | 0.59 ± 0.15 | 2.47 ± 0.5 | — | 4.2 |
| 43b | E-CH=CHCl | Cl | 0.42 ± 0.04 | 1.13 ± 0.27 | — | 2.7 |
| 43c | Z-CH=CHCl | Cl | 0.22 ± 0.02 | 0.88 ± 0.05 | — | 4.0 |
| 43d | E-CH=CHC$_6$H$_5$ | Cl | 0.31 ± 0.04 | 0.66 ± 0.01 | — | 2.1 |
| 43e | Z-CH=CHC$_6$H$_5$ | Cl | 0.14 ± 0.07 | 0.31 ± 0.09 | — | 2.2 |
| 43f | CH$_2$CH$_3$ | Cl | 2.17 ± 0.20 | 2.35 ± 0.52 | — | 1.1 |
| 43 g | (CH$_2$)$_2$CH$_3$ | Cl | 0.94 ± 0.08 | 1.08 ± 0.05 | — | 1.1 |
| 43h | (CH$_2$)$_3$CH$_3$ | Cl | 1.21 ± 0.18 | 0.84 ± 0.05 | — | 0.7 |
| 43i | (CH$_2$)$_5$CH$_3$ | Cl | 156 ± 15 | 271 ± 3 | — | 1.7 |
| 43j | (CH$_2$)$_2$C$_6$H$_5$ | Cl | 1.43 ± 0.03 | 1.54 ± 0.08 | — | 1.0 |
| 44a | (CH$_2$)$_2$CH$_3$ | CH$_3$ | 1.57 | 1.10 | 10.3 | 0.7 |
| 44b | (CH$_2$)$_3$CH$_3$ | CH$_3$ | 1.82 | 1.31 | 15.1 | 0.7 |
| 45 | (CH$_2$)$_2$CH$_3$ | H | 74.9 | 30.2 | 389 | 0.4 |
| 46 | (CH$_2$)$_2$CH$_3$ | F | 21.1 | 12.1 | 99.6 | 0.6 |
| 47a | (CH$_2$)$_2$CH$_3$ | CH$_3$ | 8.91 | 11.8 | 50.1 | 1.3 |
| 47b | (CH$_2$)$_3$CH$_3$ | CH$_3$ | 11.4 | 10.1 | 51.0 | 0.9 |
$^a$K$_i$ value for displacement of WIN 35428. $^b$IC$_{50}$ value.

### Irreversible covalent (cf. ionic) C2 ligands

Irreversible (phenylisothiocyanate) binding ligand (Murthy, V.; Martin, T. J.; Kim, S.; Davies, H. M. L.; Childers, S. R. (2008). "In Vivo Characterization of a Novel Phenylisothiocyanate Tropane Analog at Monoamine Transporters in Rat Brain". Journal of Pharmacology and Experimental Therapeutics. 326 (2): 587–595. doi:10.1124/jpet.108.138842. PMID 18492949. S2CID 5996473.) RTI-76: 4′-isothiocyanatophenyl (1R,2S,3S,5S)-3-(4-chlorophenyl)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate. Also known as: 3β-(p-chlorophenyl)tropan-2β-carboxylic acid p-isothiocyanatophenylmethyl ester.

#### C2 Acyl, N8 phenylisothiocyanate

HD-205 (Murthy et al., 2007)
Note the contrast to the phenylisothiocyanate covalent binding site locations as compared to the one on p-Isococ, a non-phenyltropane cocaine analogue.

### Benztropine based (C2-position hetero-substituted) phenyltropanes

2-(Diarylmethoxymethyl)-3β-aryltropanes & 2β-[3-(Diarylmethoxy)propyl]-3β-aryltropanes. :
| Compound | R | X | Y | [$^3$H]WIN 35,428 @ DAT K$_i$ (nM) | [$^3$H]Citalopram @ SERT K$_i$ (nM) | [$^3$H]Nisoxetine @ NET K$_i$ (nM) | [$^3$H]Pirenzepine @ M$_1$ K$_i$ (nM) |
| 9a | CH$_3$ | H | H | 34 ± 2 | 121 ± 19 | 684 ± 100 | 10,600 ± 1,100 |
| 9b | F | H | H | 49 ± 12 | — | — | — |
| 9c | Cl | H | H | 52 ± 2.1 | 147 ± 8 | 1,190 ± 72 | 11,000 ± 1,290 |
| 9d | CH$_3$ | Cl | H | 80 ± 9 | 443 ± 60 | 4,400 ± 238 | 31,600 ± 4,300 |
| 9e | F | Cl | H | 112 ± 11 | — | — | — |
| 9f | Cl | Cl | H | 76 ± 7 | 462 ± 36 | 2,056 ± 236 | 39,900 ± 5,050 |
| 9g | CH$_3$ | F | F | 62 ± 7 | 233 ± 24 | 1,830 ± 177 | 15,500 ± 1,400 |
| 9h | F | F | F | 63 ± 13 | — | — | — |
| 9i | Cl | F | F | 99 ± 18 | 245 ± 16 | 2,890 ± 222 | 16,300 ± 1,300 |
| 10a | CH$_3$ | H | H | 455 ± 36 | 530 ± 72 | 2,609 ± 195 | 12,600 ± 1,790 |
| 10c | Cl | H | H | 478 ± 72 | 408 ± 16 | 3,998 ± 256 | 11,500 ± 1,720 |
| 10d | CH$_3$ | Cl | H | 937 ± 84 | 1,001 ± 109 | 22,500 ± 2,821 | 18,200 ± 2,600 |
| 10f | Cl | Cl | H | 553 ± 106 | 1,293 ± 40 | 5,600 ± 183 | 9,600 ± 600 |
| 10g | CH$_3$ | F | F | 690 ± 76 | 786 ± 67 | 16,000 ± 637 | 9,700 ± 900 |
| 10i | Cl | F | F | 250 ± 40 | 724 ± 100 | 52,300 ± 13,600 | 9,930 ± 1,090 |
| 12a | H | H | H | 139 ± 15 | 61 ± 9 | 207 ± 30 | 7,970 ± 631 |
| 12b | H | Cl | H | 261 ± 19 | 45 ± 3 | — | 24,600 ± 2,930 |
| 12c | H | F | F | 60 ± 7 | — | — | — |

### F&B series (Biotin side-chains etc.)

One patent claims a series of compounds with biotin-related sidechains are pesticides.
| Code | para-X | C2-Tropane Position | config | DA | NE | 5-HT |
| — | H | F1 | β,β | — | — | — |
| RTI-224 | Me | F1$^c$ | β,β | 4.49 | — | 155.6 |
| RTI-233 | Me | F2 | β,β | 4.38 | 516 | 73.6 |
| RTI-235 | Me | F3$^d$ | β,β | 1.75 | 402 | 72.4 |
| — | — | F3 | β,β | — | — | — |
| RTI-236 | Me | B1$^d$ | β,β | 1.63 | 86.8 | 138 |
| RTI-237 | Me | B2$^d$ | β,β | 7.27 | 258 | 363 |
| RTI-244 | Me | B3$^d$ | β,β | 15.6 | 1809 | 33.7 |
| RTI-245 | Cl | F4$^c$ | β,β | 77.3 | — | — |
| RTI-246 | Me | F4$^c$ | β,β | 50.3 | 3000 | — |
| — | — | F5 | β,β | — | — | — |
| RTI-248 | Cl | F6$^c$ | β,β | 9.73 | 4674 | 6.96 |
| RTI-249 | Cl | F1$^c$ | β,β | 8.32 | 5023 | 81.6 |
| RTI-266 | Me | F2 | β,β | 4.80 | 836 | 842 |
| RTI-267 | Me | F7 wrong | β,β | 2.52 | 324 | 455 |
| RTI-268 | Me | F7 right | β,β | 3.89 | 1014 | 382 |
| RTI-269 | Me | F8 | β,β | 5.55 | 788 | 986 |

### Miscellany (i.e. Misc./Miscellaneous) C2-substituents

| Code | X | 2 Position | config | 8 | DA | 5-HT | NE |
| RTI-102 | I | CO$_2$H | β,β | NMe | 474 | 1928 | 43,400 |
| RTI-103 | Br | CO$_2$H | β,β | NMe | 278 | 3070 | 17,400 |
| RTI-104 | F | CO$_2$H | β,β | NMe | 2744 | >100K | >100K |
| RTI-108 | Cl | -CH$_2$Cl | β,β | NMe | 2.64 | 98 | 129.8 |
| RTI-241 | Me | -CH$_2$CO$_2$Me | β,β | NMe | 1.02 | 619 | 124 |
| RTI-139 | Cl | -CH$_3$ | β,β | NMe | 1.67 | 85 | 57 |
| RTI-161 | Cl | -C≡N | β,β | NMe | 13.1 | 1887 | 2516 |
| RTI-230 | Cl | H$_3$C–C=CH$_2$ | β,β | NMe | 1.28 | 57 | 141 |
| RTI-240 | Cl | -CHMe$_2$ | β,β | NMe | 1.38 | 38.4 | 84.5 |
| RTI-145 | Cl | -CH$_2$OCO$_2$Me | β,β | NMe | 9.60 | 2,932 | 1,478 |
| RTI-158 | Me | -C≡N | β,β | NMe | 57 | 5095 | 1624 |
| RTI-131 | Me | -CH$_2$NH$_2$ | β,β | NMe | 10.5 | 855 | 120 |
| RTI-164 | Me | -CH$_2$NHMe | β,β | NMe | 13.6 | 2246 | 280 |
| RTI-132 | Me | -CH$_2$NMe$_2$ | β,β | NMe | 3.48 | 206 | 137 |
| RTI-239 | Me | -CHMe$_2$ | β,β | NMe | 0.61 | 114 | 35.6 |
| RTI-338 | Et | -CO$_2$CH$_2$Ph | β,β | NMe | 1104 | 7.41 | 3366 |
| RTI-348 | H | -Ph | β,β | NMe | 28.2 | >34,000 | 2670 |

## C2-truncated/descarboxyl (non-ecgonine w/o 2-position-replacement tropanes)
### Aryl-Tropenes

WO 2004113297, Peters, Dan; Olsen, Gunnar M. & Nielsen, Elsebet Oestergaard et al., "Aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors", published 2004-12-29, assigned to NeuroSearch AS
| Test compound | DA-uptake IC$_{50}$(μM) | NA-uptake IC$_{50}$(μM) | 5-HT-uptake IC$_{50}$(μM) |
| (+)-3-(4-Chlorophenyl)-8-H-aza-bicyclo[3.2.1]oct-2-ene | 0.26 | 0.028 | 0.010 |
| (+)-3-Napthalen-2-yl-8-azabicyclo[3.2.1]oct-2-ene | 0.058 | 0.013 | 0.00034 |
| (–)-8-Methyl-3-(naphthalen-2-yl)-8-azabicylo[3.2.1]oct-2-ene | 0.034 | 0.018 | 0.00023 |
8-AZABICYCLO[3.2.1]OCT-2-ENE DERIVATIVES :
| Test Compound | DA uptake IC$_{50}$(μM) | NE uptake IC$_{50}$(μM) | 5-HT uptake IC$_{50}$(μM) |
| (±)-3-(3,4-Dichlorophenyl)-8-methyl-8-azabicyclo[3.2.1]oct-2-ene | 0.079 | 0.026 | 0.0047 |
U.S. patent 2,001,047,028
| Test Compound | DA uptake IC$_{50}$(μM) | NE uptake IC$_{50}$(μM) | 5-HT uptake IC$_{50}$(μM) |
| (±)-3-(4-cyanophenyl)-8-methyl-8-azabicyclo[3.2.1]oct-2-ene | 18 | 4.9 | 0.047 |
| (±)-3-(4-nitrophenyl)-8-methyl-8-azabicyclo[3.2.1]oct-2-ene | 1.5 | 0.5 | 0.016 |
| (±)-3-(4-trifluoromethoxyphenyl)-8-methyl-8-azabicyclo[3.2.1]oct-2-ene | 22.00 | 8.00 | 0.0036 |

## Enantioselective nonstandard configurations (non-2β-,3β-)
### β,α Stereochemistry

| Compound (RTI #) (S. Singh's #) | X | 2 Group | config | 8 | DAT IC$_{50}$ (nM) [$^3$H]WIN 35428 | 5-HTT IC$_{50}$ (nM) [$^3$H]paroxetine | NET IC$_{50}$ (nM) [$^3$H]nisoxetine | selectivity 5-HTT/DAT | selectivity NET/DAT |
| RTI-140 20a | H | CO$_2$Me | β,α | NMe | 101 ± 16 | 5,701 ± 721 | 2,076 ± 285 | 56.4 | 20.6 |
| RTI-352$^ɑ$ 20d | I | CO$_2$Me | β,α | NMe | 2.86 ± 0.16 | 64.9 ± 1.97 | 52.4 ± 4.9 | 22.8 | 18.4 |
| RTI-549 | Br | CO$_2$Me | β,α | NMe | — | — | — | — | — |
| RTI-319$^b$ | 3α-2-naphthyl | CO$_2$Me | β,α | NMe | 1.1 ± 0.09 | 11.4 ± 1.3 | 70.2 ± 6.28 | — | — |
| RTI-286$^c$ 20b | F | CO$_2$Me | β,α | NMe | 21 ± 0.57 | 5062 ± 485 | 1231 ± 91 | 241 | 58.6 |
| RTI-274$^d$ | F | CH$_2$O(3′,4′-MD-phenyl) | β,α | NH | 3.96 | 5.62 | 14.4 | — | — |
| RTI-287 | Et | CO$_2$Me | β,α | NMe | 327 | 1687 | 17,819 | — | — |
| 20c | Cl | CO$_2$Me | β,α | NMe | 2.4 ± 0.2 | 998 ± 120 | 60.1 ± 2.4 | 416 | 25.0 |
| 20e | Me | CO$_2$Me | β,α | NMe | 10.2 ± 0.08 | 4250 ± 422 | 275 ± 24 | 417 | 27.0 |
| | Bn | CO$_2$Me | β,α | NMe | — | — | — | — | — |

### α,β Stereochemistry

CA 2112084
| Compound | DA (μM) | M.E.D. (mg/kg) | Dose (mg/kg) | Activity | Activity |
| (2R,3S)-2-(4-chlorophenoxymethyl)-8-methyl-3-(3-chlorophenyl)-8-azabicyclo[3.2.1]octane | 0.39 | <1 | 50 | 0 | 0 |
| (2R,3S)-2-(carboxymethyl)-8-methyl-3-(2-naphthyl)-8-azabicyclo[3.2.1]octane | 0.1 | 1 | 25 | 0 | 0 |
| (2R,3S)-2-(carboxymethyl)-8-methyl-3-(3,4-dichlorophenyl)-8-azabicyclo[3.2.1]octane | 0.016 | 0.25 | 50 | + | +++ |

#### di-chloro; para- & meta- in tandem (α,β configured phenyltropanes)

U.S. patent 2,001,047,028
| Compound | X | 2 Group | config | 8 | DA | 5-HT | NE |
| Brasofensine | Cl$_2$ | methyl aldoxime | α,β | NMe | — | — | — |
| Tesofensine | Cl$_2$ | ethoxymethyl | α,β | NMe | 65 | 11 | 1.7 |
| NS-2359 (GSK-372,475) | Cl$_2$ | Methoxymethyl | α,β | NH | — | — | — |

#### fumaric acid salts (of α,β configured phenyltropanes)

WO 2004072075, Peters, Dan; Nielsen, Elsebet Oestergaard & Olsen, Gunnar M. et al., "Novel 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors", published 2004-08-26, assigned to NeuroSearch AS
| Test Compound | DA uptake IC$_{50}$(μM) | NE uptake IC$_{50}$(μM) | 5-HT uptake IC$_{50}$(μM) |
| (2R,3S)-2-(2,3-dichlorophenoxymethyl)-8-methyl-3-(3-chlorophenyl)-8-azabicyclo[3.2.1]octane fumaric acid salt | 0.062 | 0.035 | 0.00072 |
| (2R,3S)-2-(Naphthaleneoxymethane)-8-methyl-3-(3-chlorophenyl)-8-azabicyclo[3.2.1]octane fumaric acid salt | 0.062 | 0.15 | 0.0063 |
| (2R,3S)-2-(2,3-dichlorophenoxymethyl)-8-H-3-(3-chlorophenyl)-8-azabicyclo[3.2.1]octane fumaric acid salt | 0.10 | 0.048 | 0.0062 |
| (2R,3S)-2-(Naphthlyloxymethane)-8-H-3-(3-chlorophenyl)-8-azabicyclo[3.2.1]octane fumaric acid salt | 0.088 | 0.051 | 0.013 |

## Arene equivalent alterations
### η$^6$-3β-(transition metal complexed phenyl)tropanes

Unlike metal complexed PTs created with the intention of making useful radioligands, 21a & 21b were produced seeing as their η$^6$-coordinated moiety dramatically altered the electronic character and reactivity of the benzene ring, as well as such a change adding asymmetrical molecular volume to the otherwise planar arene ring unit of the molecule. (cf. the Dewar–Chatt–Duncanson model). In addition the planar dimension of the transition metal stacked arene becomes delocalized (cf. Bloom and Wheeler.).
21a was twice as potent as both cocaine and troparil in displacement of β-CFT, as well as displaying high & low affinity K$_i$ values in the same manner as those two compounds. Whereas its inhibition of DA uptake showed it as comparably equipotent to cocaine & troparil. 21b by contrast had a one hundredfold decrease in high-affinity site binding compared to cocaine and a potency 10× less for inhibiting DA uptake. Attesting these as true examples relating useful effective applications for bioorganometallic chemistry.
The discrepancy in binding for the two benzene metal chelates is assumed to be due to electrostatic differences rather than their respective size difference. The solid cone angles, measured by the steric parameter (i.e. θ) is θ=131° for Cr(CO)$_3$ whereas Cp*Ru was θ=187° or only 30% larger. The tricarbonyl moiety being considered equivalent to the cyclopenta dienyl (Cp) ligand.
Displacement of Receptor-Bound [$^3$H]WIN 35428 and Inhibition of [$^3$H]DA Uptake by Transition Metal Complexes of 3β-Phenyltropanes :
| Structure | Compound # (S. Singh) Systematic name | K$_i$ (nM)$^ɑ$ | IC$_{50}$ (nM) | selectivity binding/uptake |
| | 21a$^c$ | 17 ± 15$^b$ 224 ± 83 | 418 | 24.6 |
| | 21b$^d$ | 2280 ± 183 | 3890 | 1.7 |
| Cocaine | Cocaine | 32 ± 5 388 ±221 | 405 | 12.6 |
| Troparil (11a) | Troparil (11a) | 33 ± 17 314 ± 222 | 373 | 11.3 |
* $^ɑ$The binding data fit a two-site model better than a one-site model
* $^b$The K$_i$ value for the one-site model was 124 ± 10 nM
* $^c$IUPAC: [η$^6$-(2β-carbomethoxy-3β-phenyl)tropane]tricarbonylchromium
* $^d$IUPAC: [η$^5$-(pentamethylcyclopentadienyl)]-[η$^6$-(2β-carbomethoxy-3β-phenyl)tropane]ruthenium-(II) triflate

### 3-(2-thiophene) and 3-(2-furan)

| Code | Compound | DA (μM) | NE (μM) | 5-HT (μM) |
| 1 | (2R,3S)-2-(2,3-Dichlorophenoxymethyl)-8-methyl-3-(2-thienyl)-8-aza-bicyclo[3.2.1]octanefumaric acid salt | 0.30 | 0.0019 | 0.00052 |
| 2 | (2R,3S)-2-(1-Naphthyloxymethyl)-8-methyl-3-(2-thienyl)-8-aza-bicyclo-[3.2.1]octane fumaric acid salt | 0.36 | 0.0036 | 0.00042 |
| 3 | (2R,3S)-2-(2,3-Dichlorophenoxymethyl)-8-methyl-3-(2-furanyl)-8-aza-bicyclo-[3.2.1]octane fumaric acid salt | 0.31 | 0.00090 | 0.00036 |
| 4 | (2R,3S)-2-(1-Naphthyloxymethyl)-8-methyl-3-(2-furanyl)-8-aza-bicyclo-[3.2.1]octane fumaric acid salt | 0.92 | 0.0030 | 0.00053 |
| 5 | (2R,3S)-2-(2,3-Dichlorophenoxymethyl)-8-H-3-(2-thienyl)-8-aza-bicyclo[3.2.1]octane fumaric acid salt | 0.074 | 0.0018 | 0.00074 |
| 6 | (2R,3S)-2-(1-Naphthyloxymethyl)-8-H-3-(2-thienyl)-8-aza-bicyclo[3.2.1]octane fumaric acid salt | 0.19 | 0.0016 | 0.00054 |

### Diaryl

* Fluoxetine homologue, also: Hanna et al. (2007) cf. the paroxetine homologue PTs
* ZIENT:

## 6/7-tropane position substituted
### 2β-carbomethoxy 6/7 substituted

6/7-Substituted 2-carbomethoxy-phenyltropanes :
| Compound # (S. Singh) | Substitution | DAT (IC$_{50}$ nM) displacement of [H$^3$]WIN 35428 | 5-HTT (IC$_{50}$ nM) [H$^3$]Citalopram | Selectivity 5-HTT/DAT |
| Cocaine | H | 65 ± 12 | - | - |
| 103a | 3β,2β, 7-OMe 3′,4′-Cl$_2$ | 86 ± 4.7 | 884 ± 100 | 10.3 |
| 103b | 3β,2β, 7-OH 3′,4′-Cl$_2$ | 1.42 ± 0.03 | 28.6 ± 7.8 | 20.1 |
| 103c | 3α,2β, 7-OH 3′,4′-Cl$_2$ | 1.19 ± 0.16 | 1390 ± 56 | 1168 |
| 104a | 3β,2β, 6-OH 4′-Me | 215$^ɑ$ | - | - |
| 104b | 3β,2α, 6-OH 4′-Me | 15310$^ɑ$ | - | - |
| 104c | 3α,2β, 6-OH 4′-Me | 930$^ɑ$ | - | - |
| 104d | 3α,2α, 6-OH 4′-Me | 7860$^ɑ$ | - | - |
* $^ɑ$IC$_{50}$ value for displacement of [H$^3$]mazindol. IC$_{50}$ for cocaine 288 nM for displacement of [H$^3$]mazindol

### 3-butyl 6/7 substituted

6/7-Substituted 3-butyl-phenyltropanes :
| Compound # (S. Singh) | Substituent | K$_i$ nM displacement of [H$^3$]mazindol binding | K$_i$ nM [H$^3$]DA uptake | Selectivity uptake/binding |
| Cocaine | H | 270 ± 0.03 | 400 ± 20 | 1.5 |
| 121a | 7β-CN | 2020 ± 10 | 710 ± 40 | 0.3 |
| 121b | 6β-CN | 3040 ± 480 | 6030 ± 880 | 2.0 |
| 121c | 7β-SO$_2$Ph | 4010 ± 310 | 8280 ± 1340 | 2.1 |
| 121d | 6β-SO$_2$Ph | 4450 ± 430 | 8270 ± 690 | 1.8 |
| 121e | 7α-OH | 830 ± 40 | 780 ± 60 | 0.9 |
| 121f | H | 100 ± 10 | 61 ± 10 | 0.6 |
| 121g | 7β-CN | 24000 ± 3420 | 32100 ± 8540 | 1.3 |
| 121h | 6β-CN | 11300 ± 1540 | 26600 ± 3330 | 2.3 |
| 121i | 7β-SO$_2$Ph | 7690 ± 2770 | 7050 ± 450 | 0.9 |
| 121j | 6β-SO$_2$Ph | 4190 ± 700 | 8590 ± 1360 | 2.0 |
| 121k | 7α-SO$_2$Ph | 3420 ± 1100 | - | - |
| 121l | 7β-SO$_2$Ph, 7α-F | 840 ± 260 | 2520 ± 290 | 3.0 |
| 121m | 7α-F | 200 ± 10 | 680 ± 10 | 3.4 |
| 121n | 7β-F | 500 ± 10 | 550 ± 140 | 1.1 |

### intermediate 6- & 7-position synthesis modified phenyltropanes

6/7-synthetic intermediates :
| Compound # (S. Singh) | Substituent W | Substituent X | Substituent Y | Substituent Z |
| (±)-122a | CN | H | H | H |
| (±)-122b | H | H | CH | H |
| (±)-122c | H | CH | H | H |
| (±)-122d | H | H | H | CH |
| (±)-122e | SO$_2$Ph | H | H | H |
| (±)-122f | H | H | SO$_2$Ph | H |
| (±)-122g | H | SO$_2$Ph | H | H |
| (±)-122h | SO$_2$Ph | F | H | H |
| (±)-122i | F | SO$_2$Ph | H | H |
| (±)-122j | H | H | SO$_2$Ph | F |

## 8-tropane (bridgehead) position modified
### Nortropanes (N-demethylated)

It is well established that electrostatic potential around the para position tends to improve MAT binding. This is believed to also be the case for the meta position, although it is less studied. N-demethylation dramatically potentiates NET and SERT affinity, but the effects of this on DAT binding are insignificant. Of course, this is not always the case. For an interesting exception to this trend, see the Taxil document. There is ample evidence suggesting that N-demethylation of alkaloids occurs naturally in vivo via a biological enzyme. The fact that hydrolysis of the ester leads to inactive metabolites means that this is still the main mode of deactivation for analogues that have an easily metabolised 2-ester substituent. The attached table provides good illustration of the effect of this chemical transformation on MAT binding affinities. N.B. In the case of both nocaine and pethidine, N-demethyl compounds are more toxic and have a decreased seizure threshold.
Selected ββ Nortropanes :
| Code (S.S. #) | X para $^{(unlesspositionotherwisegiveninline)}$ | DA | 5HT | NE |
| RTI-142 75b | F | 4.39 | 68.6 | 18.8 |
| RTI-98 75d Nor$^ɑ$-RTI-55 | I | 0.69 | 0.36 | 11.0 |
| RTI-110 75c | Cl | 0.62 | 4.13 | 5.45 |
| RTI-173 75f | Et | 49.9 | 8.13 | 122 |
| RTI-279 Nor$^ɑ$-RTI-280 | para-Me meta-I | 5.98 ± 0.48 | 1.06 ± 0.10 | 74.3 ± 3.8 |
| RTI-305 Nor$^ɑ$-RTI-360/11y | Ethynyl | 1.24 ± 0.11 | 1.59 ± 0.2 | 21.8 ± 1.0 |
| RTI-307 Nor$^ɑ$-RTI-281/11z | Propynyl | 6.11 ± 0.67 | 3.16 ± 0.33 | 115.6 ± 5.1 |
| RTI-309 Nor$^ɑ$-11t | Vinyl | 1.73 ± 0.05 | 2.25 ± 0.17 | 14.9 ± 1.18 |
| RTI-330 Nor$^ɑ$-11s | Isopropyl | 310.2 ± 21 | 15.1 ± 0.97 | — |
| RTI-353 | para-Et meta-I | 330.54 ± 17.12 | 0.69 ± 0.07 | 148.4 ± 9.15 |
$^ɑ$The N-demethylated variant of (i.e. compound code-name after dash)
N-demethylating various β,β p-HC-phenyltropanes :
| N-Me compound code# → N-demethylated derivative compound code # | para-X | [$^3$H]Paroxetine | [$^3$H]WIN 35,428 | [$^3$H]Nisoxetine |
| 11 g→75f | Ethyl | 28.4 → 8.13 | 55 → 49.9 | 4,029 → 122 |
| 11t→75i | Vinyl | 9.5 → 2.25 | 1.24 → 1.73 | 78 → 14.9 |
| 11y→75n | Ethynyl | 4.4 → 1.59 | 1.2 → 1.24 | 83.2 → 21.8 |
| 11r→75 g | 1-Propyl | 70.4 → 26 | 68.5 → 212 | 3,920 → 532 |
| 11v→75k | trans-propenyl | 11.4 → 1.3 | 5.29 → 28.6 | 1,590 → 54 |
| 11w→75l | cis-propenyl | 7.09 → 1.15 | 15 → 31.6 | 2,800 → 147 |
| 11x→75 m | Allyl | 28.4 → 6.2 | 32.8 → 56.5 | 2,480 → 89.7 |
| 11z→75o | 1-Propynyl | 15.7 → 3.16 | 2.37 → 6.11 | 820 → 116 |
| 11s→75h | i-Propyl | 191 → 15.1 | 597 → 310 | 75,000 → ? |
| 11u→75j | 2-Propenyl | 3.13 → 0.6 | 14.4 → 23 | 1,330? → 144 |
N-Demethylating phenyltropanes to find a NRI :
| Isomer | 4′ | 3′ | NE | DA | 5HT |
| β,β | Me | H | 60 → 7.2 | 1.7 → 0.84 | 240 → 135 |
| β,β | F | H | 835 → 18.8 | 15.7 → 4.4 | 760 → 68.6 |
| β,β | Cl | H | 37 → 5.45 | 1.12 → 0.62 | 45 → 4.13 |
| β,α | Me | H | 270 → 9 | 10.2 → 33.6 | 4250 → 500 |
| β,α | F | H | 1200 → 9.8 | 21 → 32.6 | 5060 → 92.4 |
| β,α | Cl | H | 60 → 5.41 | 2.4 → 3.1 | 998 → 53.3 |
| β,α | F | Me | 148 → 4.23 | 13.7 → 9.38 | 1161 → 69.8 |
| β,α | Me | F | 44.7 → 0.86 | 7.38 → 9 | 1150 → 97.4 |
"Interest in NET selective drugs continues as evidenced by the development of atomoxetine, manifaxine, and reboxetine as new NET selective compounds for treating ADHD and other CNS disorders such as depression" (FIC, et al. 2005).
N-norphenyltropanes :
| Short Name (S. Singh) | Para-X | DAT [$^3$H]WIN 35428 IC$_{50}$ (nM) | 5-HTT [$^3$H]Paroxetine IC$_{50}$ (nM) | NET [$^3$H]Nisoxetine IC$_{50}$ (nM) | Selectivity 5-HTT/DAT | Selectivity NET/DAT |
| Norcocaine | H | 206 ± 29 | 127 ± 13 | 139 ± 9 | 0.6 | 0.7 |
| 75a | H | 30.8 ± 2.3 | 156 ± 8 | 84.5 ± 7.5 | 5.1 | 2.7 |
| 75b | F | 4.39 ± 0.20 | 68.6 ± 2.0 | 18.8 ± 0.7 | 15.6 | 4.3 |
| 75c | Cl | 0.62 ± 0.09 | 4.13 ± 0.62 | 5.45 ± 0.21 | 6.7 | 8.8 |
| 75d | I | 0.69 ± 0.2 | 0.36 ± 0.05 | 7.54 ± 3.19 | 0.5 | 10.9 |
| 75e | para-I & 2β-CO$_2$CH(CH$_3$)$_2$ | 1.06 ± 0.12 | 3.59 ± 0.27 | 132 ± 5 | 3.4 | 124 |
| 75f | C$_2$H$_5$ | 49.9 ± 7.3 | 8.13 ± 0.30 | 122 ± 12 | 0.2 | 2.4 |
| 75g | n-C$_3$H$_7$ | 212 ± 17 | 26 ± 1.3 | 532 ± 8.1 | 0.1 | 2.5 |
| 75h | CH(CH$_3$)$_2$ | 310 ± 21 | 15.1 ± 0.97 | - | 0.05 | - |
| 75i | CH=CH$_2$ | 1.73 ± 0.05 | 2.25 ± 0.17 | 14.9 ± 1.18 | 1.3 | 8.6 |
| 75j | C-CH$_3$ ║ CH$_2$ | 23 ± 0.9 | 0.6 ± 0.06 | 144 ± 12 | 0.03 | 6.3 |
| 75k | trans-CH=CHCH$_3$ | 28.6 ± 3.1 | 1.3 ± 0.1 | 54 ± 16 | 0.04 | 1.9 |
| 75l | cis-CH=CHCH$_3$ | 31.6 ± 2.2 | 1.15 ± 0.1 | 147 ± 4.3 | 0.04 | 4.6 |
| 75m | CH$_2$CH=CH$_2$ | 56.5 ± 56 | 6.2 ± 0.3 | 89.7 ± 9.6 | 0.1 | 1.6 |
| 75n | CH≡CH | 1.24 ± 0.11 | 1.59 ± 0.2 | 21.8 ± 1.0 | 1.3 | 17.6 |
| 75o | CH≡CCH$_3$ | 6.11 ± 0.67 | 3.16 ± 0.33 | 116 ± 5.1 | 0.5 | 19.0 |
| 75p$^ɑ$ | 3,4-Cl$_2$ | 0.66 ± 0.24 | 1.4$^b$ | - | 2.1 | - |
$^ɑ$These values determined in Cynomolgus monkey caudate-putamen $^b$The radioligand used for 5-HTT was [$^3$H]citalopram
2β-Propanoyl-N-norphenyltropanes :
| Short Name (S. Singh) | DAT [$^{125}$I]RTI-55 IC$_{50}$ (nM) | 5-HTT [$^3$H]Paroxetine K$_i$ (nM) | NET [$^3$H]Nisoxetine K$_i$ (nM) | Selectivity 5-HTT/DAT | Selectivity NET/DAT |
| 79a | 0.07 ± 0.01 | 0.22 ± 0.16 | 2.0 ± 0.09 | 3.1 | 28.6 |
| 79b | 4.7 ± 0.58 | 19 ± 1.4 | 5.5 ± 2.0 | 4.0 | 1.2 |
| 79c | 380 ± 110 | 5.3 ± 1.0 | 3400 ± 270 | 0.01 | 8.9 |
| 79d | 190 ± 17 | 150 ± 50 | 5100 ± 220 | 0.8 | 26.8 |
| 79e | 490 ± 120 | 85 ± 16 | 4300 ± 1100 | 0.1 | 8.8 |
| 79f | 1.5 ± 1.1 | 0.32 ± 0.06 | 10.9 ± 1.5 | 0.2 | 7.3 |
| 79g | 16 ± 4.9 | 0.11 ± 0.02 | 94 ± 18 | 0.07 | 5.9 |

#### Paroxetine homologues

See the N-methyl paroxetine homologues cf. di-aryl phenyltropanes for another SSRI approximated hybrid: the fluoxetine based homologue of the phenyltropane class.
2-(3,4-(Methylenedioxy)phenoxy)methyl-norphenyltropane binding potencies :
| Short Name (S. Singh) | Stereochemistry | DAT [$^3$H]WIN 35428 IC$_{50}$ (nM) | 5-HTT [$^3$H]Paroxetine IC$_{50}$ (nM) | NET [$^3$H]Nisoxetine IC$_{50}$ (nM) | Selectivity 5-HTT/DAT | Selectivity NET/DAT |
| Paroxetine | - | 623 ± 25 | 0.28 ± 0.02 | 535 ± 15 | 0.0004 | 0.8 |
| R-81a | 2β,3β | 835 ± 90 | 480 ± 21 | 37400 ± 1400 | 0.6 | 44.8 |
| R-81b | 2α,3β | 142 ± 13 | 90 ± 3.4 | 2500 ± 250 | 0.6 | 17.6 |
| R-81c | 2β,3α | 3.86 ± 0.2 | 5.62 ± 0.2 | 14.4 ± 1.3 | 1.4 | 3.7 |
| S-81d | 2β,3β | 1210 ± 33 | 424 ± 15 | 17300 ± 1800 | 0.3 | 14.3 |
| S-81e | 2α,3β | 27.6 ± 2.4 | 55.8 ± 5.73 | 1690 ± 150 | 2.0 | 61.2 |
| S-81f | 2β,3α | 407 ± 33 | 19 ± 1.8 | 1990 ± 176 | 0.05 | 4.9 |

### N-replaced (S,O,C)

The eight position nitrogen has been found to not be an exclusively necessary functional anchor for binding at the MAT for phenyltropanes and related compounds. Sulfurs, oxygens, and even the removal of any heteroatom, leaving only the carbon skeleton of the structure at the bridged position, still show distinct affinity for the monoamine transporter cocaine-target site and continue to form an ionic bond with a measurable degree of reasonable efficacy.
| Compound | X | 2 Group | config | 8 | DA | 5-HT | NE |
| Tropoxane | Cl,Cl | CO$_2$Me | (racemic) β,β | O | 3.3 | 6.5 | No data |
| O-4210 | p-F | 3-methyl-5-isoxazole | β,β | S | 7.0 | >1000 | No data |

#### 8-oxa bridgehead replacements

8-Oxanortropanes, binding inhibition using monkey caudate-putamen :
| Compound # (S. Singh) | Para- (meta-) | DAT (IC$_{50}$ nM) displacement of [H$^3$]WIN 35428 | 5-HTT (IC$_{50}$ nM) [H$^3$]Citalopram | Selectivity 5-HTT/DAT |
| R/S-90a | H | >1000 | >1000 | - |
| R/S-90b | F | 546 | 2580 | 4.7 |
| R/S-90c | Cl | 10 | 107 | 10.7 |
| R/S-90d | Br | 22 | 30 | 1.4 |
| R/S-90e | I | 7 | 12 | 1.7 |
| R/S-90f | 3,4-Cl$_2$ | 3.35 | 6.52 | 1.9 |
| R-90g | 3,4-Cl$_2$ | 3.27 | 4.67 | 1.4 |
| S-90h | 3,4-Cl$_2$ | 47 | 58 | 1.2 |
| R/S-91a | H | 1990 | 11440 | 5.7 |
| R/S-91b | F | >1000 | >10000 | - |
| R/S-91c | Cl | 28.5 | 816 | 28.6 |
| R/S-91d | Br | 9 | 276 | 30.7 |
| R/S-91e | I | 42 | 72 | 1.7 |
| R/S-91f | 3,4-Cl$_2$ | 3.08 | 64.5 | 20.9 |
| R-91g | 3,4-Cl$_2$ | 2.34 | 31 | 13.2 |
| S-91h | 3,4-Cl$_2$ | 56 | 2860 | 51.1 |

#### 8-carba bridgehead replacements

8-carba 3-Aryl bicyclo[3.2.1]octanes :
| Compound # (S. Singh) | DAT (IC$_{50}$ nM) displacement of [H$^3$]WIN 35428 | 5-HTT (IC$_{50}$ nM) [H$^3$]Citalopram | Selectivity 5-HTT/DAT |
| R/S-98a | 7.1 ± 1.7 | 5160 ± 580 | 726 |
| R/S-98b | 9.6 ± 1.8 | 33.4 ± 0.6 | 3.5 |
| R/S-98c | 14.3 ± 1.1 | 180 ± 65 | 12.6 |

### N-alkyl

| Compound | X | 2 Group | config | 8 | DAT | SERT | NET |
| FP-β-CPPIT | Cl | 3′-phenylisoxazol-5′-yl | β,β | NCH$_2$CH$_2$CH$_2$F | - | - | - |
| FE-β-CPPIT | Cl | (3′-phenylisoxazol-5′-yl) | β,β | NCH$_2$CH$_2$F | - | - | - |
| Altropane (IACFT) | F | CO$_2$Me | β,β | NCH$_2$CH=CHF | - | - | - |
| FECNT | I | CO$_2$Me | β,β | NCH$_2$CH$_2$F | - | - | - |
| RTI-310 U.S. patent 5,736,123 | I | CO$_2$Me | β,β | N-Pr$^n$ | 1.17 | - | - |
| RTI-311 | I | CO$_2$Me | β,β | NCH$_2$CH=CH$_2$ | 1.79 | - | - |
| RTI-312 U.S. patent 5,736,123 | I | CO$_2$Me | β,β | NBu$^n$ | 0.76 | - | - |
| RTI-313 U.S. patent 5,736,123 | I | CO$_2$Me | β,β | NCH$_2$CH$_2$CH$_2$F | 1.67 | - | - |
| Ioflupane (FP-CIT) | $^{123}$I | CO$_2$Me | β,β | NCH$_2$CH$_2$CH$_2$F | - | - | - |
| PE2I | Me | CO$_2$Me | β,β | NCH$_2$CH=CHI | - | - | - |
| RTI-251 | Cl | CO$_2$Me | β,β | NCH$_2$CO$_2$Et | 1.93 | 10.1 | 114 |
| RTI-252 | Cl | CO$_2$Me | β,β | NCH$_2$CH$_2$CO$_2$Et | 2.56 | 35.2 | 125 |
| RTI-242 | Cl | β,β (bridged) -C(O)CH(CO$_2$Me)CH$_2$N | β,β (bridged) -C(O)CH(CO$_2$Me)CH$_2$N | β,β (bridged) -C(O)CH(CO$_2$Me)CH$_2$N | 7.67 | 227 | 510 |
Bi- and tri-cyclic aza compounds and their uses.
N-substituted 3β-phenylnortropanes (including N-phthalimidoalkyl analogues of β-CIT) :
| Short Name (S. Singh) | Nitrogen side-chain (N8) | DAT [$^3$H]GBR 12935 K$_i$ (nM) | 5-HTT [$^3$H]Paroxetine K$_i$ (nM) | NET [$^3$H]Nisoxetine K$_i$ (nM) | Selectivity 5-HTT/DAT | Selectivity NET/DAT |
| Cocaine | H | 350 ± 80 | >10000 | >30000 | >28.6 | - |
| GBR 12909 | - | 0.06 ± 0.02 | 52.8 ± 4.4 | >20000 | 880 | - |
| WIN 35428 11b | H | 14.7 ± 2.9 | 181 ± 21 | 635 ± 110 | 12.3 | 43.2 |
| RTI-55 11e | H | 1.40 ± 0.20 | 0.46 ± 0.06 | 2.80 ± 0.40 | 0.3 | 2 |
| 82a | CH$_2$CH=CH$_2$ | 22.6 ± 2.9$^ɑ$ | - | - | - | - |
| 82b | CH$_2$CH$_2$CH$_3$ | 43.0 ± 17.7$^ɑ$ | - | - | - | - |
| 82c | CH$_2$C$_6$H$_5$ | 58.9 ± 1.65$^b$ | 1073$^c$ | - | 18.2 | - |
| 82d | (CH$_2$)$_3$C$_6$H$_5$ | 1.4 ± 0.2$^b$ | 133 ± 7$^c$ | - | 95.0 | - |
| 82e | (CH$_2$)$_5$C$_6$H$_5$ | 3.4 ± 0.83$^b$ | 49.9 ± 10.2$^c$ | - | 14.7 | - |
| 83a | CH$_2$CH$_2$CH$_2$F | 1.20 ± 0.29 | 48.7 ± 8.4 | 10000 | 40.6 | 8333 |
| 83b | CH$_2$CH$_2$F | 4.40 ± 0.35 | 21.7 ± 8.3 | >10000 | 4.9 | - |
| 84a | CH$_2$CH$_2$CH$_2$F | 3.50 ± 0.39 | 0.110 ± 0.02 | 63.0 ± 4.0 | 0.03 | 18 |
| 84b | CH$_2$CH$_2$F | 4.00 ± 0.73 | 0.140 ± 0.02 | 93.0 ± 17.0 | 0.03 | 23.2 |
| 84c | CH$_2$CHF$_2$ | 15.1 ± 3.7 | 9.6 ± 1.5 | >5000 | 0.6 | - |
| 84d | CH$_2$CH$_2$CH$_2$Cl | 3.10 ± 0.57 | 0.32 ± 0.06 | 96.0 ± 29.0 | 0.1 | 31.0 |
| 84e | CH$_2$CH$_2$CH$_2$Br | 2.56 ± 0.57 | 0.35 ± 0.08 | 164 ± 47 | 0.1 | 64.1 |
| 84f | CH$_2$CH$_2$CH$_2$I | 38.9 ± 6.3 | 8.84 ± 0.53 | 5000 | 0.2 | 128 |
| 84g | CH$_2$...methylcyclopropane | 4.30 ± 0.87 | 1.30 ± 0.25 | 198 ± 9.6 | 0.3 | 46.0 |
| 84h | CH$_2$CH$_2$CH$_2$OH | 5.39 ± 0.21 | 2.50 ± 0.20 | 217 ± 19 | 0.5 | 40.2 |
| 84i | CH$_2$CH$_2$(OCH$_3$)$_2$ | 6.80 ± 1.10 | 1.69 ± 0.09 | 110 ± 7.7 | 0.2 | 16.2 |
| 84j | CH$_2$CO$_2$CH$_3$ | 11.9 ± 1.4 | 0.81 ± 0.10 | 29.1 ± 1.0 | 0.07 | 2.4 |
| 84k | CH$_2$CON(CH$_3$)$_2$ | 12.2 ± 3.8 | 6.40 ± 1.70 | 522 ± 145 | 0.5 | 42.8 |
| 84l | CH$_2$CH$_2$CH$_2$OMs | 36.3 ± 2.1 | 17.3 ± 1.2 | 5000 | 0.5 | 138 |
| 84m | COCH(CH$_3$)$_2$ | 2100 ± 140 | 102 ± 23 | >10000 | 0.05 | - |
| 84n | (CH$_2$)$_2$Pht | 4.23 ± 0.48 | 0.84 ± 0.02 | 441 ± 66.0 | 0.2 | 104 |
| 84o | (CH$_2$)$_3$Pht | 9.10 ± 1.10 | 0.59 ± 0.07 | 74.0 ± 11.6 | 0.06 | 8.1 |
| 84p | (CH$_2$)$_4$Pht | 2.38 ± 0.22 | 0.21 ± 0.02 | 190 ± 18.0 | 0.09 | 79.8 |
| 84q | (CH$_2$)$_5$Pht | 2.40 ± 0.17 | 0.34 ± 0.03 | 60.0 ± 3.10 | 0.1 | 25.0 |
| 84r | (CH$_2$)$_8$Pht | 2.98 ± 0.30 | 0.20 ± 0.02 | 75.0 ± 3.6 | 0.07 | 25.2 |
| 84s$^d$ | CH$_2$CH=CH-CH$_3$ | 15 ± 1 | 75 ± 5 | 400 ± 80 | 5.0 | 26.7 |
| 84t$^d$ | CH$_2$C(Br)=CH$_2$ | 30 ± 5 | 200 ± 40 | >1000 | 6.7 | - |
| 84u$^d$ | CH$_2$CH=CH$_2$I(E) | 30 ± 5 | 960 ± 60 | 295 ± 33 | 32.0 | 9.8 |
| 84v$^d$ | CH$_2$C≡CH | 14 ± 1 | 100 ± 30 | >1000 | 7.1 | - |
| 84w$^d$ | CH$_2$C$_6$H$_5$ | 42 ± 12 | 100 ± 17 | 600 ± 100 | 2.4 | 14.3 |
| 84x$^d$ | CH$_2$C$_6$H$_4$-2-CH$_3$ | 93 ± 19 | 225 ± 40 | >1000 | 2.4 | - |
| 85a$^d$ | para-H | 113 ± 41 | 100 ± 20 | >1000 | 0.9 | - |
| 85b$^d$ | para-Cl, meta-Cl | 29 ± 4 | 50 ± 6 | 500 ± 120 | 1.7 | 17.2 |
| 85c$^d$ | para-Me | 17 ± 7 | 500 ± 30 | >1000 | 29.4 | - |
| 85d$^d$ | para-CH(CH$_3$)$_2$ | 500 ± 120 | 450 ± 80 | >1000 | 0.9 | - |
| 85e$^d$ | para-n-C$_3$H$_7$ | 500 ± 100 | 300 ± 12 | 750 ± 160 | 0.6 | 1.5 |
* $^ɑ$IC$_{50}$ for displacement of [$^3$H]cocaine. IC$_{50}$ for cocaine = 67.8 ± 8.7 (nM)
* $^b$IC$_{50}$ values for displacement of [$^3$H]WIN 35428
* $^c$IC$_{50}$ values for displacement of [$^3$H]citalopram
* $^d$The standard K$_i$ value for the displacement of [$^3$H]GBR 12935, [$^3$H]paroxetine, and [$^3$H]nisoxetine were 27 ± 2, 3 ± 0.2, and 80 ± 28 nM, respectively, for these experiments
3β-(4-alkylthiophenyl)nortropanes :
| Structure | Compound | R$_1$ | R$_2$ | Inhibition of [$^3$H]WIN 35,428 @ DAT IC$_{50}$ (nM) | Inhibition of [$^3$H]Paroxetine @ 5-HTT K$_i$ (nM) | Inhibition of [$^3$H]Nisoxetine @ NET K$_i$ (nM) | NET/DAT (uptake ratio) | NET/5-HTT (uptake ratio) |
| See 7a—7h table |
| See 7a—7h table | 7a | CH$_3$ | CH$_3$ | 9 ± 3 | 0.7 ± 0.2 | 220 ± 10 | 24 | 314 |
| See 7a—7h table | 7b | C$_2$H$_5$ | CH$_3$ | 232 ± 34 | 4.5 ± 0.5 | 1170 ± 300 | 5 | 260 |
| | 8a | CH$_3$ | H | 28 ± 6 | 0.19 ± 0.01 | 21 ± 6 | 0.8 | 110 |
| | 8b | C$_2$H$_5$ | H | 177 ± 62 | 1.26 ± 0.05 | 118 ± 13 | 0.7 | 94 |
| | 9a | CH$_3$ | FCH$_2$CH$_2$CH$_2$ | 112 ± 2 | 3 ± 1 | 960 ± 100 | 9 | 320 |
| | 9b | C$_2$H$_5$ | FCH$_2$CH$_2$CH$_2$ | 1,200 ± 200 | 27 ± 2 | >2,000 | 2 | 74 |
| | 10a | CH$_3$ | CH$_2$=CH$_2$CH$_2$ | 71 ± 25 | 5.5 ± 0.8 | 2,000 ± 500 | 28 | 364 |
| | 10b | C$_2$H$_5$ | CH$_2$=CH$_2$CH$_2$ | 1,100 ± 100 | 47 ± 3 | >2,000 | 2 | 43 |
| | 11a | CH$_3$ | CH$_3$CH$_2$CH$_2$ | 74 ± 20 | 5.7 ± 0.6 | 1,200 ± 140 | 16 | 211 |
| | 11b | C$_2$H$_5$ | CH$_3$CH$_2$CH$_2$ | 900 ± 300 | 49 ± 6 | >2,000 | 2 | 41 |

### Bridged N-constrained phenyltropanes (fused/tethered)

See: Bridged cocaine derivatives & N8 Tricyclic (2β—crossed-over) N8—to—3β replaced aryl linked (expansive front-bridged) cocaine analogues

#### p-methyl aryl front & back N-bridged phenyltropanes

U.S. patent 6,150,376
Activity at monoamine transporters: Binding Affinities & MAT Inhibition of Bridged Phenyltropanes K$_i$ (nM) :
| Compound # (S. Singh's #) | 2β=R | [$^3$H]Mazindol binding | [$^3$H]DA uptake | [$^3$H]5-HT uptake | [$^3$H]NE uptake | selectivity [$^3$H]5-HT/[$^3$H]DA |
| cocaine | CO$_2$CH$_3$ | 375 ± 68 | 423 ± 147 | 155 ± 40 | 83.3 ± 1.5 | 0.4 |
| (–)-40 (–)-128 | | 54.3 ± 10.2 | 60.3 ± 0.4 | 1.76 ± 0.23 | 5.24 ± 0.07 | 0.03 |
| (+)-40 (+)-128 | | 79 ± 19 | 114 ± 28 | 1.48 ± 0.07 | 4.62 ± 0.31 | 0.01 |
| (±)-40 (±)-128 | | 61.7 ± 8.5 | 60.3 ± 0.4 | 2.32 ± 0.23 | 2.69 ± 0.12 | 0.04 |
| 29β | | 620 | 1420 | 8030 | — | — |
| 30β | | 186 | 492 | 97.7 | — | — |
| 31β | | 47.0 | 211 | 28.5 | — | — |
| 29α | | 4140 | 20100 | 3920 | — | — |
| 30α | | 3960 | 8850 | 696 | 1150 | — |
| 45 129 | | 6.86 ± 0.43 | 24.0 ± 1.3 | 1.77 ± 0.04 | 1.06 ± 0.03 | 0.07 |
| 42a 131a | n-Bu | 4.00 ± 0.07 | 2.23 ± 0.12 | 14.0 ± 0.6 | 2.99 ± 0.17 | 6.3 |
| 41a 130a | n-Bu | 17.2 ± 1.13 | 10.2 ± 1.4 | 78.9 ± 0.9 | 15.0 ± 0.4 | 7.8 |
| 42b 131b | Et | 3.61 ± 0.43 | 11.3 ± 1.1 | 25.7 ± 4.3 | 4.43 ± 0.01 | 2.3 |
| 50a 133a | n-Bu | 149 ± 6 | 149 ± 2 | 810 ± 80 | 51.7 ± 12 | 5.4 |
| 49a 132a | n-Bu | 13.7 ± 0.8 | 14.2 ± 0.1 | 618 ± 87 | 3.84 ± 0.35 | 43.5 |
| (–)-4 | | 10500 | 16500 | 1890 | 70900 | — |
| (+)-4 | | 18500 | 27600 | 4630 | 38300 | — |
| (–)-5 | | 9740 | 9050 | 11900 | 4650 | — |
| (+)-5 | | 6770 | 10500 | 25100 | 4530 | — |
| RTI-4229/Coc-242 | N8/2β-C(O)CH(CO2Me)CH2N para-chloro | — | 7.67 ± 0.31$^ɑ$ | 226.54 ± 27.37$^b$ | 510.1 ± 51.4$^c$ | — |
* $^ɑ$Value for displacement of [$^3$H]WIN 35,428 binding @ DAT
* $^b$Value for displacement of [$^3$H]paroxetine binding to SERT
* $^c$Value for displacement of [$^3$H]nisoxetine from NET
Fused tropane-derivatives as neurotransmitter reuptake inhibitors. Singh notes that all bridged derivatives tested displayed 2.5—104 fold higher DAT affinity than cocaine. The ones 2.8—190 fold more potent at DAT also had increased potency at the other two MAT sites (NET & SERT); NET having 1.6—78× increased activity. (+)-128 additionally exhibited 100× greater potency @ SERT, whereas 132a & 133a had 4–5.2× weaker 5-HTT (i.e. SERT) activity. Front-bridged (e.g. 128 & 129) had a better 5-HT/DA reuptake ratio in favor of SERT, while the back-bridged (e.g. 130–133) preferred placement with DAT interaction. U.S. patent 5,998,405

#### 3,4-Cl$_2$ aryl front-bridged phenyltropanes

| Code | Compound | DA (μM) | NE (μM) | 5-HT (μM) |
| 1 | (1 S,2S,4S,7R)-2-(3,4-Dichloro- phenyl)-8-azatricyclo[5.4.0.0$^{4,8}$]- undecan-11 -one O-methyl-oxime | 0.012 | 0.0020 | 0.0033 |
| 2 | (1 S,2S,4S,7R)-2-(3,4-Dichloro- phenyl)-8-azatricyclo[5.4.0.0$^{4,8}$]- undecan-11-one | 0.18 | 0.035 | 0.0075 |
| 3 | (1 S,3S,4S,8R)-3-(3,4-Dichloro-phenyl)-7-azatricyclo[5.3.0.04,8]- decan-5-one O-methyl-oxime | 0.0160 | 0.0009 | 0.0032 |
| 4 | (1 S,2S,4S,7R)-2-(3,4-Dichloro-phenyl)-8-azatricyclo[5.4.0.04,8]- undecan-11-ol | 0.0750 | 0.0041 | 0.0028 |
| 5 | (1 S,3S,4S,8R)-3-(3,4-Dichloro-phenyl)-7-azatricyclo[5.3.0.04,8]- decan-5-one | 0.12 | 0.0052 | 0.0026 |
| 6 | (1 S,3S,4S,8R)-3-(3,4-Dichloro- phenyl)-7-azatricyclo[5.3.0.04,8]-decan-5-ol | 0.25 | 0.0074 | 0.0018 |
| 7 | (1S,3S,4S,8R)-3- (3,4-Dichloro- phenyl)-7-azatricyclo[5.3.0.04,8]dec- 5-yl acetate | 0.21 | 0.0061 | 0.0075 |
| 8 | (1S,3S,4S,8R)-3-(3,4-Dichlorophenyl)-5-methoxy-7- azatricyclo[5.3.0.04,8]decane | 0.022 | 0.0014 | 0.0001 |
* 1-Chloroethyl chloroformate is used to remove N-methyl of trans-aryltropanes.
* 2° amine is reacted with Br(CH$_2$)nCO$_2$Et.
* Base used to abstract proton α- to CO$_2$Et group and complete the tricyclic ring closure step (Dieckmann cyclization).
To make a different type of analog (see Kozikowski patent above)
* Remove N-Me
* Add ɣ-bromo-chloropropane
* Allow for cyclization with K$_2$CO$_3$ base and KI cat.

#### C2 + C3 (side-chain) fused (carboxylate & benzene conjoined)

(1R,2S,10R,12S)-15-methyl-15-azatetracyclo(10.2.1.0$^2$,$^{10}$.0$^4$,$^9$)pentadeca-4(9),5,7-trien-3-one

#### C3 to 1′ + 2′ (ortho) tropane locant dual arene bridged

Parent compound of a series of spirocyclic cocaine benzoyl linkage modification analogs created by Suzuki coupling method of ortho-substituted arylboronic acids and an enol-triflate derived from cocaine; which technically has the three methylene length of cocaine analogues as well as the single length which defines the phenyltropane series. Note that the carbomethoxyl group is (due to constraints in synthetic processes used in the creation of this compound) alpha configured; which is not the usual, most prevalent, conformation favored for the PT cocaine-receptor binding pocket of most such sub-type of chemicals. The above and below depictions show attested compounds synthesized, additionally with variations upon the Endo–exo isomerism of their structures.

## Cycloalkane-ring alterations of the tropane ring system
### Azanonane (outer ring extended)

3-Phenyl-9-azabicyclo[3.3.1]nonane derivatives
To better elucidate the binding requirements at MAT, the methylene unit on the tropane was extended by one to create the azanonane analogs. Which are the beginning of classes of modifications that start to become effected by the concerns & influences of macrocyclic stereocontrol.
Despite the loosened flexibility of the ring system, nitrogen constrained variants (such as were created to make the bridged class of phenyltropanes) which might better fit the rigid placement necessary to suit the spatial requirements needed in the binding pocket were not synthesized. Though front-bridged types were synthesized for the piperidine homologues: the trend of equal values for either isomers of that type followed the opposing trend of a smaller and lessened plasticity of the molecule to contend with a rationale for further constraining the pharmacophore within that scope. Instead such findings lend credence to the potential for the efficacy of fusing the nitrogen on an enlarged tropane, as like upon the compounds given below.
[3.3.1]azanonane analogues displacement of bound [$^3$H]WIN 35428 :
| Compound # (S. Singh) | K$_i$ (nM) |
| Cocaine | 32 ± 5 390 ± 220 |
| WIN 35065-2 | 33 ± 17 310 ± 220 |
| 146a | 4600 ± 510 |
| 146b | 5730 ± 570 |
| 146c | 3450 ± 310 |
| 146d | 3470 ± 350 |
| 147 | 13900 ± 2010 |

### Azabornane (outer ring contracted)

3-Phenyl-7-azabicyclo[2.2.1]heptane derivatives
Ring-contracted analogs of phenyltropanes did not permit sufficient penetration of the phenyl into the target binding site on MAT for an affinity in the efficacious range. The distance from the nitrogen to the phenyl centroid for 155a was 4.2 and 155c was 5.0 Å, respectively. (Whereas troparil was 5.6 & compound 20a 5.5 angstroms). However piperidine homologues (discussed below) had comparable potencies.
Azabornanes with longer substitutions at the 3β-position (benzoyloxys alkylphenyls, carbamoyls etc.) or with the nitrogen in the position it would be on the piperidine homologues (i.e. arrangements of differing locations for the nitrogens being either distal or proximal within the terms required to facilitate the framework of the compound to a correlative proportion, functional for the given moiety), were not synthesized, despite conclusions that the nitrogen to phenyl length was the issue at variance enough to be the interfering factor for the proper binding of the compressed topology of the azabornane. Carroll, however, has listed benzoyloxy azabornanes in patents.
[2.2.1]azabornane analogues displacement of bound [$^3$H]WIN 35428 :
| Compound # (S. Singh) | K$_i$ (nM) |
| Cocaine | 32 ± 5 390 ± 220 |
| WIN 35065-2 | 33 ± 17 310 ± 220 |
| 155a | 60,400 ± 4,800 |
| 155b | 96,500 ± 42 |
| 155c | 5,620 ± 390 |
| 155d | 18,900 ± 1,700 |

### Piperidine homologues (inner two-carbon bridge excised)

Piperidine homologues had comparable affinity & potency spreads to their respective phenyltropane analogues. Without as much of a discrepancy between the differing isomers of the piperidine class with respect to affinity and binding values as had in the phenyltropanes.

#### p-chloro & related (piperidine homologues of phenyltropanes)

Phenyltropane 4-aryl-3-carboalkoxy-piperidine analogues :
| Compound # (S. Singh) | X = para- / 4′- Substitution | R = 2-tropane position | DAT (IC$_{50}$ nM) [H$^3$]WIN 35428 binding displacement | DA (IC$_{50}$ nM) [H$^3$]DA uptake | Selectivity Uptake/Binding |
| Cocaine | H | CO$_2$Me | 102 ± 9 | 239 ± 1 | 2.3 |
| (±)-166a | Cl | β-CO$_2$CH$_3$ | 53.7 ± 1.9 | 37.8 ± 7.9 | 0.7 |
| (-)-166a | Cl | β-CO$_2$CH$_3$ | 24.8 ± 1.6 | 85.2 ± 2.6 | 3.4 |
| (+)-166a | Cl | β-CO$_2$CH$_3$ | 1360 ± 125 | 5090 ± 172 | 3.7 |
| (-)-167a | Cl | β-CO$_2$OH | 75.3 ± 6.2 | 49.0 ± 3.0 | 0.6 |
| (+)-167a | Cl | β-CO$_2$OH | 442 ± 32 | — | — |
| (-)-168a | Cl | β-CO$_2$OAc | 44.7 ± 10.5 | 62.9 ± 2.7 | 1.4 |
| (+)-168a | Cl | β-CO$_2$OAc | 928 ± 43 | 2023 ± 82 | 2.2 |
| (-)-169a | Cl | β-n-Pr | 3.0 ± 0.5 | 8.3 ± 0.6 | 2.8 |
| (-)-170a | H | β-CO$_2$CH$_3$ | 769 ± 19 | — | — |
| (±)-166b | Cl | α-CO$_2$CH$_3$ | 197 ± 8 | — | — |
| (+)-166b | Cl | α-CO$_2$CH$_3$ | 57.3 ± 8.1 | 34.6 ± 3.2 | 0.6 |
| (-)-166b | Cl | α-CO$_2$CH$_3$ | 653 ± 38 | 195 ± 8 | 0.3 |
| (+)-167b | Cl | α-CO$_2$OH | 240 ± 18 | 683 ± 47 | 2.8 |
| (+)-168b | Cl | α-CO$_2$OAc | 461 ± 11 | — | — |
| (+)-169b | Cl | α-n-Pr | 17.2 ± 0.5 | 23.2 ± 2.2 | 1.3 |
Heterocyclic N-Desmethyl

#### Naphthyl & related (piperidine homologues of phenyltropanes)

Activity @ MAT for piperidine homologues of phenyltropanes, including naphthyl derivatives :
| Compound # | [$^3$H]DA uptake (nM) IC$_{50}$ | [$^3$H]DA uptake (nM) Ki | [$^3$H]NE uptake (nM) IC$_{50}$ | [$^3$H]NE uptake (nM) Ki | [$^3$H]5-HTT uptake (nM) IC$_{50}$ | [$^3$H]5-HTT uptake (nM) Ki | Uptake Ratio DA/5-HT (Ki) | Uptake Ratio NE/5-HT (Ki) |
| Cocaine | 459 ± 159 | 423 ± 147 | 127 ± 4.1 | 108 ± 3.5 | 168 ± 0.4 | 155 ± 0.4 | 2.7 | 0.69 |
| Fluoxetine | >4500 | >2500 | 193 ± 4.1 | 176 ± 3.5 | 8.1 ± 0.7 | 7.3 ± 0.7 | 624 | 24 |
| 20 | 75 ± 9.1 | 69 ± 8.1 | 101 ± 3.3 | 88 ± 2.9 | 440 ± 30 | 391 ± 27 | 0.18 | 0.23 |
| 6 | 23 ± 1.0 | 21 ± 0.9 | - | 34 ± 0.8 | 8.2 ± 0.3 | 7.6 ± 0.2 | 2.8 | 4.5 |
| 7 | >1000 | 947 ± 135 | - | 241 ± 1.7 | 8.2 ± 0.3 | 7.6 ± 0.2 | 22.6 | 5.7 |
| 8 | 94 ± 9.6 | 87 ± 8.9 | - | 27 ± 1.6 | 209 ± 17 | 192 ± 16 | 0.45 | 0.14 |
| 9 | 293 ± 6.4 | 271 ± 5.9 | - | 38 ± 4.0 | 13 ± 0.7 | 12 ± 0.7 | 23 | 3.2 |
| 19 | 97 ± 8.6 | 90 ± 8.0 | 34 ± 2.5 | 30 ± 2.3 | 3.9 ± 0.5 | 3.5 ± 0.5 | 26 | 8.6 |
| 10 | 326 ± 1.2 | 304 ± 1.1 | 337 ± 37 | 281 ± 30 | 113 ± 4.3 | 101 ± 3.8 | 3.0 | 2.8 |
| 14 | 144 ± 20 | 131 ± 18 | 204 ± 5.6 | 175 ± 4.8 | 155 ± 3.9 | 138 ± 3.5 | 0.95 | 1.3 |
| 15 | >1800 | >1700 | >1300 | >1100 | 275 ± 39 | 255 ± 37 | >6 | >4 |
| 16 | >1000 | 964 ± 100 | >1200 | >1000 | 334 ± 48 | 309 ± 44 | 3.1 | 3.5 |
| 17 | 213 ± 30 | 187 ± 26 | 399 ± 12 | 364 ± 9.2 | 189 ± 37 | 175 ± 34 | 1.1 | 2.1 |
| 18 | 184 ± 30 | 173 ± 26 | 239 ± 42 | 203 ± 36 | 67 ± 4.5 | 62 ± 4.1 | 2.8 | 3.3 |

#### distal-nitrogen 'dimethylamine' (piperidine-like cyclohexyl homologues of phenyltropanes)

Source:
cf. Fencamfamine

## Radiolabeled

| Code | SERT K$_i$ (nM) | NET K$_i$ (nM) | DAT K$_i$ (nM) | Radiolabel | In vivo study |
| 1 | 0.2 | 102.2 | 29.9 | $^{11}$C | Non-human primate |
| 2 | 0.2 | 31.7 | 32.6 | $^{11}$C | Non-human primate |
| 3 | 0.05 | 24 | 3.47 | $^{123}$I | Rat |
| 4 | 0.08 | 28 | 13 | $^{18}$F | Non-human primate |
| 5 | 0.11 | 450 | 22 | $^{11}$C | Rat, monkey |
* IPT (N-3-iodoprop-(2E)-ene-2β-carbomethoxy-3β-(4′-chlorophenyl)tropane), can be radiolabeled with $^{123}$I or $^{125}$I and used as a ligand to map several MATs
* N-4-Fluorobut-2-yn-1-yl-2β-carbomethoxy-3β-phenyltropane (PR04.MZ) often radiolabeled.
* JHC1-64. A fluorescent analog, similar in its long chain off of the nitrogen bridge similar to the transition metal phenyltropane types.

### Transition metal complexes

These compounds include transition metals in their heteroatomic conformation, unlike non-radiolabel intended chelates where their element is chosen for intrinsic affectation to binding and function, these are tagged on by a "tail" (or similar) with a sufficient spacer to remain separated from known binding properties and instead are meant to add radioactivity enough to be easily tracked via observation methods that utilize radioactivity. As for anomalies of binding within the spectrum of the under-written kinds just mentioned: other factors not otherwise considered to account for its relatively lower potency, "compound 89c" is posited to protrude forward at the aryl place on its moiety toward the MAT ligand acceptor site in a manner detrimental to its efficacy. That is considered due to the steric bulk of the eight-position "tail" chelate substituted constituent, overreaching the means by which it was intended to be isolated from binding factors upon a tail, and ultimately nonetheless, interfering with its ability to bind. However, to broach this discrepancy, decreasing of the nitrogen tether at the eight position by a single methylene unit (89d) was shown to bring the potency of the analogous compound to the expected, substantially higher, potency: The N-methyl analog of 89c having an IC$_{50}$ of 1.09 ± 0.02 @ DAT & 2.47 ± 0.14 nM @ SERT; making 89c upwards of thirty-three times weaker at those MAT uptake sites.
"Transition metal" chelated phenyltropanes :
| Structure | Compound # (S. Singh) | X = para- / 4′- Substitution | Configuration | DAT (IC$_{50}$ nM) displacement of [H$^3$]WIN 35428 | 5-HTT (IC$_{50}$ nM) [H$^3$]Citalopram | Selectivity 5-HTT/DAT |
| | WIN 35428 | F | - | 11.0 ± 1.0 | 160 ± 20 | 14.5 |
| +2β-chelated phenyltropanes |
| | 73 TRODAT-1$^ɑ$ | Cl | - | R=13.9, S=8.42$^b$ | - | - |
| | 74 TROTEC-1 | F | - | high affinity site = 0.15 ± 0.04$^c$ low affinity site = 20.3 ± 16.1$^c$ | - | - |
| N-chelated phenyltropanes |||||||
| | 89a | F | 2β | 5.99 ± 0.81 | 124 ± 17 | 20.7 |
| | 89b | F | 2α | 2960 ± 157 | 5020 ± 1880 | 1.7 |
| | 89c | 3,4-Cl$_2$ | 2β | 37.2 ± 3.4 | 264 ± 16 | 7.1 |
| | 89d | Cl | - | 0.31 ± 0.03$^d$ | - | - |
* $^ɑ$IUPAC: [2-[[2-[[[3-(4-chlorophenyl)-7-methyl-8-azabicyclo[3,2,1]oct-2-yl]methyl]-(2-mercaptoethyl)amino]ethyl]amino]ethanethiolato-(3—)-N2, N2′, S2, S2′]oxo-[1''R''-(''exo'', ''exo'')]-[99mTc]technetium
* $^b$R- & S- isomer values are K$_i$ (nM) for displacement of [$^{125}$I]IPT with technetium-99m replaced by rhenium
* $^c$IC$_{50}$ (nM) values for displacement of [$^3$H]WIN 35428 with ligand tricarbonyltechnetium replaced with rhenium. (IC$_{50}$ for WIN 35428 were 2.62 ± 1.06 @ high affinity binding & 139 ± 72 @ low affinity binding sites)
* $^d$K$_i$ value for displacement of [$^{125}$I]IPT radioligand.

## Select annotations of above

Phenyltropanes can be grouped by "N substitution" "Stereochemistry" "2-substitution" & by the nature of the 3-phenyl group substituent X. Often this has dramatic effects on selectivity, potency, and duration, also toxicity, since phenyltropanes are highly versatile. For more examples of interesting phenyltropanes, see some of the more recent patents, e.g. U.S. patent 6,329,520, U.S. patent 7,011,813, U.S. patent 6,531,483, and U.S. patent 7,291,737.
Potency in vitro should not be confused with the actual dosage, as pharmacokinetic factors can have a dramatic influence on what proportion of an administered dose actually gets to the target binding sites in the brain, and so a drug that is very potent at binding to the target may nevertheless have only moderate potency in vivo. For example, RTI-336 requires a higher dosage than cocaine. Accordingly, the active dosage of RTI-386 is exceedingly poor despite the relatively high ex vivo DAT binding affinity.

## Sister substances

Many molecular drug structures have exceedingly similar pharmarcology to phenyltropanes, yet by certain technicalities do not fit the phenyltropane moniker. These are namely classes of dopaminergic cocaine analogues that are in the piperidine class (a category that includes methylphenidate) or benztropine class (such as Difluoropine: which is extremely close to fitting the criteria of being a phenyltropane.) Whereas other potent DRIs are far removed from being in the phenyltropane structural family, such as Benocyclidine or Vanoxerine.
Most any variant with a tropane locant—3-β (or α) connecting linkage differing from, e.g. longer than, a single methylene unit (i.e. "phenyl"), including alkylphenyls (see the styrene analog, first image given in example below) is more correctly a "cocaine analogue" proper, and not a phenyltropane. Especially if this linkage imparts a sodium channel blocker functionality to the molecule.